alcoholic cardiomyopathy: Disease of CARDIAC MUSCLE resulting from chronic excessive alcohol consumption. Myocardial damage can be caused by: (1) a toxic effect of alcohol; (2) malnutrition in alcoholics such as THIAMINE DEFICIENCY; or (3) toxic effect of additives in alcoholic beverages such as COBALT. This disease is usually manifested by DYSPNEA and palpitations with CARDIOMEGALY and congestive heart failure (HEART FAILURE).
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519870 |
1. Apply sex-specific ruleNone |
519870 |
2. Check conditionsNone |
519870 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
209 |
4. Check minimum number of eventsNone |
209 |
5. Include endpointsNone |
209 |
6. Filter based on genotype QC (FinnGen only) |
204 |
Control definitions (FinnGen only)
- Control exclude
- I9_CARDMYO
Extra metadata
- Level in the ICD hierarchy
- C
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- I42
- Name in latin
- Cardiomyopathia alcoholica
Similar endpoints
↥List of similar endpoints to
Alcoholic cardiomyopathy
based on the number of shared cases.
Similar with more cases:
- Cardiomyopathy
- Alcohol use disorder, Swedish definition
- Alcohol related diseases, tilastokeskus definition
- Alcohol related diseases and deaths, all endpoints
- Other heart diseases, wide
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 5527 | 579 | 4785 |
| Only index persons | 1818 | 218 | 1600 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.12 | 0.02 | 0.13 |
| Only index persons | 0.05 | 0.01 | 0.06 |
| Median age at first event (years) | |||
| Whole population | 54.66 | 56.03 | 54.42 |
| Only index persons | 58.18 | 59.42 | 58.01 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 204 | 19 | 185 |
| Unadjusted period prevalence (%) | 0.08 | 0.01 | 0.08 |
| Median age at first event (years) | 60.83 | 54.85 | 61.45 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 209
- Matched controls
- 2090
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
I42.6
ICD-10 Finland
Alcoholic cardiomyopathy
+∞
246.7
185
*
I42.0
ICD-10 Finland
Dilated cardiomyopathy
+∞
75.7
68
*
201
Kela drug reimbursment
Chronic cardiac insufficiency
15.7
69.1
70
65
F10.1
ICD-10 Finland
Mental and behavioural disorders due to use of alcohol, Harmful use
10.0
52.8
76
113
C01AA05
ATC
digoxin; systemic
8.1
38.3
62
103
C03DA01
ATC
spironolactone; oral
6.5
32.9
68
144
I42.9
ICD-10 Finland
Cardiomyopathy, unspecified
+∞
31.0
29
*
F10.29
ICD-10 Finland
Addiction caused by alcohol UNS
11.2
30.6
35
37
P15
ICPC
Chronic alcohol abuse
9.5
27.8
36
45
4255A
ICD-9 Finland
Cardiomyopathy, Alcoholic cardiomyopathy
+∞
27.7
26
*
N07BB01
ATC
disulfiram; oral
7.9
25.6
39
59
K70.0
ICD-10 Finland
Alcoholic fatty liver
47.8
24.3
29
7
I50.9
ICD-10 Finland
Heart failure, unspecified
4.7
24.1
76
227
F10.25
ICD-10 Finland
Alcohol dependence continuous use
19.3
21.8
33
20
I50.1
ICD-10 Finland
Left ventricular failure
6.5
20.4
37
67
F10.40
ICD-10 Finland
Withdrawal symptoms and delirium caused by alcohol without seizures
24.5
17.3
24
11
F10.0
ICD-10 Finland
Mental and behavioural disorders due to use of alcohol, Acute intoxication
17.3
16.7
26
17
F10.26
ICD-10 Finland
Alcohol dependence periodic alcoholism
15.6
15.5
25
18
F10.2
ICD-10 Finland
Mental and behavioural disorders due to use of alcohol, Dependence syndrome
22.1
15.5
22
11
C03CA01
ATC
furosemide; systemic
3.2
15.5
105
500
K70.3
ICD-10 Finland
Alcoholic cirrhosis of liver
18.3
15.2
23
14
N05AA02
ATC
levomepromazine; systemic
6.8
14.5
24
39
A98
ICPC
Health maint/preventive medicine
0.3
14.4
124
1720
I50.0
ICD-10 Finland
Congestive heart failure
4.5
14.3
39
101
3039X
ICD-9 Finland
Alcohol dependence syndrome, Other and unspecified alcohol dependence
14.3
13.3
22
17
F10.20
ICD-10 Finland
Alcohol dependence currently independent
11.6
13.1
24
23
289
Kela drug reimbursment
Combination product containing sacubitril and valsartan
40.1
12.4
15
*
F10.00
ICD-10 Finland
Alcohol-related acute intoxication uncomplicated
12.1
12.4
22
20
F10.24
ICD-10 Finland
Alcohol depence active use
12.1
12.4
22
20
F10.31
ICD-10 Finland
Withdrawal symptoms caused by alcohol with seizures
17.8
11.9
18
11
R56.8
ICD-10 Finland
Other and unspecified convulsions
5.2
11.8
26
56
3050A
ICD-9 Finland
Nondependent abuse of drugs, Alcohol abuse
14.8
11.7
19
14
381
Kela drug reimbursment
Combination product containing sacubitril and valsartan
37.3
11.4
14
*
F10.09
ICD-10 Finland
Alcohol intoxication UNS
8.8
10.9
23
29
F10.39
ICD-10 Finland
Withdrawal symptoms caused by alcohol UNS
13.9
10.9
18
14
N05BA02
ATC
chlordiazepoxide; systemic
10.4
10.5
20
21
C09DX04
ATC
valsartan and sacubitril; oral
34.5
10.5
13
*
X69
ICD-10 Finland
Intentional self-poisoning by and exposure to other and unspecified chemicals and noxious substances
12.2
10.3
18
16
XF400
NOMESCO Finland
ECG with 12 standard connections
3.0
9.9
55
225
I48
ICD-10 Finland
Atrial fibrillation and flutter
2.6
9.7
75
365
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
2.8
9.7
60
261
R99
ICD-10 Finland
Other ill-defined and unspecified causes of mortality
5.3
9.5
20
41
N05BA01
ATC
diazepam; systemic, rectal
3.2
9.3
42
152
T36
ICD-10 Finland
Poisoning by systemic antibiotics
7.7
9.3
21
30
K03.82
ICD-10 Finland
Split tooth for reasons other than trauma
0.2
9.1
8
391
4273A
ICD-9 Finland
Cardiac dysrhythmias, Atrial fibrillation and flutter
10.2
9.0
17
18
N05CD07
ATC
temazepam; oral
3.2
8.9
41
150
FM1AE
NOMESCO Finland
Standard cardiac ultrasound examination
2.7
8.9
60
271
K70.4
ICD-10 Finland
Alcoholic hepatic failure
52.2
8.8
10
*
S82.6
ICD-10 Finland
Fracture of lateral malleolus
4.7
8.3
20
46
K70.1
ICD-10 Finland
Alcoholic hepatitis
23.1
8.1
11
5
F10.49
ICD-10 Finland
Withdrawal symptoms and delirium caused by alcohol without information about seizures
19.2
7.7
11
6
1CX08, ,
NOMESCO Finland
82.9
7.5
8
*
I42.2
ICD-10 Finland
Other hypertrophic cardiomyopathy
+∞
7.3
7
*
I42.8
ICD-10 Finland
Other cardiomyopathies
+∞
7.3
7
*
207
Kela drug reimbursment
Chronic arrhythmias
2.6
7.0
49
223
B01AA03
ATC
warfarin; systemic
2.4
7.0
59
293
N05BA04
ATC
oxazepam; oral
2.4
7.0
59
294
F10.30
ICD-10 Finland
Withdrawal symptoms caused by alcohol uncomplicated
9.8
6.9
13
14
N40
ICD-10 Finland
Hyperplasia of prostate
0.4
6.7
29
656
Z45.0
ICD-10 Finland
Adjustment and management of cardiac devices
6.1
6.6
17
30
K78
ICPC
Atrial fibrillation/flutter
3.2
6.5
27
92
F10.21
ICD-10 Finland
Alcohol dependence currently abstinent, but staying in restrictive environment
9.7
6.4
12
13
Z72.1
ICD-10 Finland
Alcohol use
9.7
6.4
12
13
4254A
ICD-9 Finland
Cardiomyopathy, Other primary cardiomyopathies
+∞
6.3
6
*
FPE37
NOMESCO Finland
Implantation of biventricular cardioverter-defibrillator with atrial and ventricular electrodes
+∞
6.3
6
*
4259X
ICD-9 Finland
Cardiomyopathy, Secondary cardiomyopathy, unspecified
+∞
6.3
6
*
M01AH05
ATC
etoricoxib; oral
0.5
6.2
57
949
EBA15
NOMESCO Finland
Extraction of multiple teeth
4.1
6.1
17
44
P16
ICPC
Acute alcohol abuse
7.6
6.0
13
18
TimeCodeWAS
↥TODO / Current known limitations:
- Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
- Legend / how to read the glyphs.
- Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
- Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
- Download CSV.
- No filters and sorters.
- Limited amount of endpoints (~400) having TimeCodeWAS data.
- Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
spironolactone; oral
C03DA01 [21601534]
C03DA01 [21601534]
2.5e+00
2.6e+00
2.3e+00
—
3.5e+00
3.6e+00
2.7e+00
cases:13.94%
controls:1.26%
cases:12.50%
controls:1.01%
cases:4.33%
controls:0.43%
—
—
cases:11.36%
controls:0.39%
cases:29.63%
controls:1.13%
cases:27.94%
controls:2.55%
29
26
179
2045
26
21
182
2050
9
9
199
2062
—
10
8
78
2061
24
23
57
2004
19
41
49
1566
digoxin; oral, parenteral
C01AA05 [21600234]
C01AA05 [21600234]
2.5e+00
2.4e+00
—
—
3.9e+00
3.3e+00
3.0e+00
cases:13.94%
controls:1.35%
cases:9.62%
controls:0.97%
—
—
—
—
cases:14.77%
controls:0.34%
cases:24.69%
controls:1.23%
cases:32.35%
controls:2.43%
29
28
179
2043
20
20
188
2051
—
—
13
7
75
2062
20
25
61
2002
22
39
46
1568
Heart failure, unspecified
I50.9 [45576879]
I50.9 [45576879]
3.0e+00
3.1e+00
3.1e+00
1.0e+50
—
3.2e+00
2.6e+00
cases:12.98%
controls:0.72%
cases:11.06%
controls:0.58%
cases:5.29%
controls:0.24%
cases:8.17%
controls:0.00%
—
—
cases:16.05%
controls:0.79%
cases:17.65%
controls:1.56%
27
15
181
2056
23
12
185
2059
11
5
197
2066
17
0
191
2071
—
13
16
68
2011
12
25
56
1582
furosemide; oral, parenteral
C03CA01 [21601518]
C03CA01 [21601518]
2.0e+00
1.9e+00
2.0e+00
—
3.4e+00
2.5e+00
2.3e+00
cases:24.04%
controls:4.15%
cases:20.19%
controls:3.62%
cases:7.21%
controls:1.01%
—
—
cases:27.27%
controls:1.26%
cases:38.27%
controls:4.83%
cases:45.59%
controls:7.72%
50
86
158
1985
42
75
166
1996
15
21
193
2050
—
24
26
64
2043
31
98
50
1929
31
124
37
1483
Atrial fibrillation and flutter
I48 [45596206]
I48 [45596206]
1.6e+00
1.8e+00
2.5e+00
1.0e+50
3.4e+00
1.7e+00
1.6e+00
cases:19.71%
controls:4.68%
cases:13.46%
controls:2.46%
cases:4.33%
controls:0.39%
cases:8.65%
controls:0.00%
cases:9.09%
controls:0.34%
cases:13.58%
controls:2.76%
cases:25.00%
controls:6.35%
41
97
167
1974
28
51
180
2020
9
8
199
2063
18
0
190
2071
8
7
80
2062
11
56
70
1971
17
102
51
1505
Internal Medicine
11 [38004456]
11 [38004456]
1.5e+00
1.6e+00
2.4e+00
1.0e+50
3.1e+00
1.9e+00
1.9e+00
cases:52.88%
controls:20.71%
cases:30.77%
controls:8.35%
cases:12.98%
controls:1.35%
cases:25.96%
controls:0.00%
cases:19.32%
controls:1.06%
cases:37.04%
controls:8.44%
cases:66.18%
controls:22.90%
110
429
98
1642
64
173
144
1898
27
28
181
2043
54
0
154
2071
17
22
71
2047
30
171
51
1856
45
368
23
1239
Left ventricular failure
I50.1 [45543181]
I50.1 [45543181]
2.6e+00
2.5e+00
—
—
—
3.7e+00
3.4e+00
cases:4.81%
controls:0.39%
cases:2.88%
controls:0.24%
—
—
—
—
—
—
cases:11.11%
controls:0.30%
cases:13.24%
controls:0.50%
10
8
198
2063
6
5
202
2066
—
—
—
9
6
72
2021
9
8
59
1599
Mental and behavioural disorders due to use of alcohol, Harmful use
F10.1 [45595844]
F10.1 [45595844]
3.1e+00
3.3e+00
—
1.0e+50
—
2.8e+00
2.5e+00
cases:16.83%
controls:0.92%
cases:9.13%
controls:0.39%
—
—
cases:4.33%
controls:0.00%
—
—
cases:7.41%
controls:0.49%
cases:14.71%
controls:1.37%
35
19
173
2052
19
8
189
2063
—
9
0
199
2071
—
6
10
75
2017
10
22
58
1585
ramipril; oral
C09AA05 [21601789]
C09AA05 [21601789]
1.2e+00
1.2e+00
1.5e+00
—
2.7e+00
2.3e+00
2.1e+00
cases:18.27%
controls:6.33%
cases:15.87%
controls:5.50%
cases:5.29%
controls:1.26%
—
—
cases:21.59%
controls:1.84%
cases:39.51%
controls:6.07%
cases:39.71%
controls:7.59%
38
131
170
1940
33
114
175
1957
11
26
197
2045
—
19
38
69
2031
32
123
49
1904
27
122
41
1485
Cardiology
6 [38004451]
6 [38004451]
9.0e-01
1.2e+00
2.0e+00
—
2.5e+00
2.4e+00
1.8e+00
cases:20.67%
controls:9.56%
cases:12.98%
controls:4.30%
cases:4.33%
controls:0.58%
—
—
cases:9.09%
controls:0.77%
cases:33.33%
controls:4.49%
cases:41.18%
controls:10.83%
43
198
165
1873
27
89
181
1982
9
12
199
2059
—
8
16
80
2053
27
91
54
1936
28
174
40
1433
bisoprolol; oral
C07AB07 [21601689]
C07AB07 [21601689]
9.9e-01
1.2e+00
1.1e+00
—
2.4e+00
2.2e+00
2.0e+00
cases:32.21%
controls:14.97%
cases:33.17%
controls:12.75%
cases:11.06%
controls:3.86%
—
—
cases:30.68%
controls:3.87%
cases:59.26%
controls:14.16%
cases:63.24%
controls:19.23%
67
310
141
1761
69
264
139
1807
23
80
185
1991
—
27
80
61
1989
48
287
33
1740
43
309
25
1298
General Practice
1 [38004446]
1 [38004446]
1.6e+00
1.8e+00
2.3e+00
—
2.7e+00
1.3e+00
7.2e-01
cases:31.73%
controls:8.35%
cases:19.71%
controls:3.86%
cases:5.77%
controls:0.58%
—
—
cases:10.23%
controls:0.72%
cases:17.28%
controls:5.38%
cases:25.00%
controls:14.00%
66
173
142
1898
41
80
167
1991
12
12
196
2059
—
9
15
79
2054
14
109
67
1918
17
225
51
1382
warfarin; oral, parenteral
B01AA03 [21600965]
B01AA03 [21600965]
1.4e+00
1.4e+00
1.5e+00
—
2.4e+00
2.3e+00
2.0e+00
cases:14.90%
controls:4.10%
cases:12.02%
controls:3.24%
cases:2.88%
controls:0.63%
—
—
cases:10.23%
controls:1.01%
cases:27.16%
controls:3.60%
cases:33.82%
controls:6.16%
31
85
177
1986
25
67
183
2004
6
13
202
2058
—
9
21
79
2048
22
73
59
1954
23
99
45
1508
Inpatient Hospital
21 [8717]
21 [8717]
9.1e-01
1.2e+00
1.8e+00
1.0e+50
2.7e+00
1.4e+00
1.4e+00
cases:45.19%
controls:24.96%
cases:25.96%
controls:9.46%
cases:9.13%
controls:1.69%
cases:25.00%
controls:0.00%
cases:15.91%
controls:1.21%
cases:28.40%
controls:9.03%
cases:61.76%
controls:28.75%
94
517
114
1554
54
196
154
1875
19
35
189
2036
52
0
156
2071
14
25
74
2044
23
183
58
1844
42
462
26
1145
Phosphatidylethanol [Mass/volume] in Blood
74661-0 [44816559]
74661-0 [44816559]
2.8e+00
3.5e+00
—
—
—
2.5e+00
—
cases:5.29%
controls:0.34%
cases:7.21%
controls:0.24%
—
—
—
—
—
—
cases:6.17%
controls:0.54%
—
—
11
7
197
2064
15
5
193
2066
—
—
—
5
11
76
2016
—
Standard cardiac ultrasound examination
FM1AE [2001303278]
FM1AE [2001303278]
1.5e+00
1.5e+00
—
1.0e+50
—
2.6e+00
3.0e+00
cases:12.02%
controls:2.90%
cases:4.33%
controls:1.01%
—
—
cases:4.33%
controls:0.00%
—
—
cases:11.11%
controls:0.94%
cases:27.94%
controls:1.93%
25
60
183
2011
9
21
199
2050
—
9
0
199
2071
—
9
19
72
2008
19
31
49
1576
Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma
33762-6 [3029187]
33762-6 [3029187]
8.6e-01
1.5e+00
2.6e+00
—
2.7e+00
1.6e+00
1.3e+00
cases:9.62%
controls:4.30%
cases:8.65%
controls:1.98%
cases:6.73%
controls:0.53%
—
—
cases:5.68%
controls:0.39%
cases:11.11%
controls:2.37%
cases:16.18%
controls:5.23%
20
89
188
1982
18
41
190
2030
14
11
194
2060
—
5
8
83
2061
9
48
72
1979
11
84
57
1523
Emergency Room Visit
ER [9203]
ER [9203]
1.2e+00
1.6e+00
2.5e+00
—
1.6e+00
1.0e+00
1.2e+00
cases:50.00%
controls:24.05%
cases:32.21%
controls:8.55%
cases:12.02%
controls:1.06%
—
—
cases:5.68%
controls:1.16%
cases:20.99%
controls:8.63%
cases:54.41%
controls:27.32%
104
498
104
1573
67
177
141
1894
25
22
183
2049
—
5
24
83
2045
17
175
64
1852
37
439
31
1168
Bilirubin.total [Moles/volume] in Serum or Plasma
14631-6 [3006140]
14631-6 [3006140]
1.2e+00
1.5e+00
2.0e+00
—
2.2e+00
9.3e-01
7.9e-01
cases:24.04%
controls:9.08%
cases:18.27%
controls:4.78%
cases:5.77%
controls:0.82%
—
—
cases:6.82%
controls:0.82%
cases:11.11%
controls:4.69%
cases:17.65%
controls:8.84%
50
188
158
1883
38
99
170
1972
12
17
196
2054
—
6
17
82
2052
9
95
72
1932
12
142
56
1465
Presence of electronic cardiac devices
Z95.0 [45571406]
Z95.0 [45571406]
1.8e+00
—
-1.0e+50
—
—
3.3e+00
3.0e+00
cases:2.40%
controls:0.39%
—
—
cases:0.00%
controls:0.29%
—
—
—
—
cases:6.17%
controls:0.25%
cases:8.82%
controls:0.50%
5
8
203
2063
—
0
6
208
2065
—
—
5
5
76
2022
6
8
62
1599
Congestive heart failure
I50.0 [45567179]
I50.0 [45567179]
—
2.9e+00
—
1.0e+50
—
3.1e+00
2.0e+00
—
—
cases:4.81%
controls:0.29%
—
—
cases:3.85%
controls:0.00%
—
—
cases:6.17%
controls:0.30%
cases:7.35%
controls:1.06%
—
10
6
198
2065
—
8
0
200
2071
—
5
6
76
2021
5
17
63
1590
potassium chloride; oral
A12BA01 [21600877]
A12BA01 [21600877]
1.9e+00
2.1e+00
—
—
—
1.9e+00
1.9e+00
cases:8.17%
controls:1.26%
cases:5.29%
controls:0.68%
—
—
—
—
—
—
cases:6.17%
controls:0.94%
cases:11.76%
controls:1.99%
17
26
191
2045
11
14
197
2057
—
—
—
5
19
76
2008
8
32
60
1575
temazepam; oral
N05CD07 [21604642]
N05CD07 [21604642]
2.0e+00
1.7e+00
2.0e+00
—
-1.0e+50
—
9.4e-01
cases:15.38%
controls:2.37%
cases:9.13%
controls:1.74%
cases:4.33%
controls:0.58%
—
—
cases:0.00%
controls:0.63%
—
—
cases:10.29%
controls:4.29%
32
49
176
2022
19
36
189
2035
9
12
199
2059
—
0
13
88
2056
—
7
69
61
1538
Psychiatry
26 [38004469]
26 [38004469]
1.5e+00
2.3e+00
—
—
—
2.0e+00
1.2e+00
cases:13.94%
controls:3.33%
cases:9.13%
controls:1.01%
—
—
—
—
—
—
cases:9.88%
controls:1.53%
cases:10.29%
controls:3.48%
29
69
179
2002
19
21
189
2050
—
—
—
8
31
73
1996
7
56
61
1551
magnesium hydroxide; oral
G04BX01 [21602658]
G04BX01 [21602658]
2.5e+00
—
—
—
—
—
3.2e+00
cases:4.33%
controls:0.39%
—
—
—
—
—
—
—
—
—
—
cases:8.82%
controls:0.37%
9
8
199
2063
—
—
—
—
—
6
6
62
1601
magnesium hydroxide; oral
A02AA04 [21600052]
A02AA04 [21600052]
2.5e+00
—
—
—
—
—
3.2e+00
cases:4.33%
controls:0.39%
—
—
—
—
—
—
—
—
—
—
cases:8.82%
controls:0.37%
9
8
199
2063
—
—
—
—
—
6
6
62
1601
ECG with 12 standard connections
XF400 [2001303368]
XF400 [2001303368]
1.7e+00
2.2e+00
—
—
—
—
1.7e+00
cases:11.06%
controls:2.27%
cases:3.85%
controls:0.43%
—
—
—
—
—
—
—
—
cases:10.29%
controls:2.05%
23
47
185
2024
8
9
200
2062
—
—
—
—
7
33
61
1574
Prothrombin time (PT) actual/Normal
5894-1 [3033658]
5894-1 [3033658]
1.3e+00
1.8e+00
2.5e+00
—
—
1.2e+00
7.7e-01
cases:15.87%
controls:4.97%
cases:12.02%
controls:2.27%
cases:2.88%
controls:0.24%
—
—
—
—
cases:7.41%
controls:2.32%
cases:7.35%
controls:3.55%
33
103
175
1968
25
47
183
2024
6
5
202
2066
—
—
6
47
75
1980
5
57
63
1550
oxazepam; oral
N05BA04 [21604569]
N05BA04 [21604569]
1.6e+00
1.9e+00
—
—
—
1.9e+00
1.1e+00
cases:13.94%
controls:3.24%
cases:11.54%
controls:1.83%
—
—
—
—
—
—
cases:12.35%
controls:1.97%
cases:10.29%
controls:3.55%
29
67
179
2004
24
38
184
2033
—
—
—
10
40
71
1987
7
57
61
1550
Emergency Room and Inpatient Visit
ERIP [262]
ERIP [262]
1.3e+00
1.6e+00
2.5e+00
—
—
—
5.5e-01
cases:15.87%
controls:5.12%
cases:12.50%
controls:2.85%
cases:3.37%
controls:0.29%
—
—
—
—
—
—
cases:8.82%
controls:5.29%
33
106
175
1965
26
59
182
2012
7
6
201
2065
—
—
—
6
85
62
1522
zopiclone; oral
N05CF01 [21604654]
N05CF01 [21604654]
1.0e+00
1.1e+00
1.6e+00
—
2.0e+00
9.5e-01
1.2e+00
cases:14.90%
controls:5.79%
cases:10.58%
controls:3.86%
cases:3.37%
controls:0.72%
—
—
cases:6.82%
controls:0.97%
cases:9.88%
controls:4.05%
cases:20.59%
controls:7.53%
31
120
177
1951
22
80
186
1991
7
15
201
2056
—
6
20
82
2049
8
82
73
1945
14
121
54
1486
levomepromazine; oral, parenteral
N05AA02 [21604493]
N05AA02 [21604493]
2.6e+00
2.7e+00
—
—
—
-1.0e+50
—
cases:4.81%
controls:0.39%
cases:3.37%
controls:0.24%
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
10
8
198
2063
7
5
201
2066
—
—
—
0
9
81
2018
—
disulfiram; oral
N07BB01 [21604821]
N07BB01 [21604821]
2.6e+00
2.5e+00
—
—
—
—
—
cases:6.73%
controls:0.53%
cases:2.88%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
14
11
194
2060
6
5
202
2066
—
—
—
—
—
Medical doctor
Z2221 [2001311556]
Z2221 [2001311556]
9.7e-01
—
—
1.0e+50
—
2.5e+00
2.4e+00
cases:6.25%
controls:2.46%
—
—
—
—
cases:3.37%
controls:0.00%
—
—
cases:8.64%
controls:0.74%
cases:22.06%
controls:2.61%
13
51
195
2020
—
—
7
0
201
2071
—
7
15
74
2012
15
42
53
1565
Home Visit
OMOP4822459 [581476]
OMOP4822459 [581476]
1.0e+00
1.7e+00
1.6e+00
—
—
—
—
cases:7.69%
controls:2.85%
cases:9.13%
controls:1.83%
cases:3.85%
controls:0.77%
—
—
—
—
—
—
—
—
16
59
192
2012
19
38
189
2033
8
16
200
2055
—
—
—
—
Supine thorax X-ray examination
GD1QA [2001303648]
GD1QA [2001303648]
2.2e+00
2.0e+00
—
—
—
—
1.2e+00
cases:7.69%
controls:0.87%
cases:2.88%
controls:0.39%
—
—
—
—
—
—
—
—
cases:7.35%
controls:2.36%
16
18
192
2053
6
8
202
2063
—
—
—
—
5
38
63
1569
Iron/Transferrin [Ratio] in Serum or Plasma
60517-0 [40763571]
60517-0 [40763571]
1.7e+00
8.6e-01
2.5e+00
—
—
—
1.2e+00
cases:9.62%
controls:1.93%
cases:3.37%
controls:1.45%
cases:2.88%
controls:0.24%
—
—
—
—
—
—
cases:7.35%
controls:2.36%
20
40
188
2031
7
30
201
2041
6
5
202
2066
—
—
—
5
38
63
1569
Chronic arrhythmias
207 [2001600205]
207 [2001600205]
1.6e+00
—
—
—
—
—
2.4e+00
cases:8.17%
controls:1.69%
—
—
—
—
—
—
—
—
—
—
cases:7.35%
controls:0.75%
17
35
191
2036
—
—
—
—
—
5
12
63
1595
Amylase.pancreatic [Enzymatic activity/volume] in Serum or Plasma
1805-1 [3016417]
1805-1 [3016417]
1.9e+00
2.1e+00
—
—
—
—
—
cases:8.17%
controls:1.30%
cases:5.77%
controls:0.77%
—
—
—
—
—
—
—
—
—
—
17
27
191
2044
12
16
196
2055
—
—
—
—
—
Inpatient Visit
IP [9201]
IP [9201]
5.5e-01
1.2e+00
1.5e+00
1.0e+50
2.7e+00
1.3e+00
6.0e-01
cases:18.27%
controls:11.44%
cases:9.13%
controls:2.99%
cases:2.40%
controls:0.53%
cases:5.29%
controls:0.00%
cases:6.82%
controls:0.48%
cases:11.11%
controls:3.40%
cases:8.82%
controls:5.04%
38
237
170
1834
19
62
189
2009
5
11
203
2060
11
0
197
2071
6
10
82
2059
9
69
72
1958
6
81
62
1526
Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma
2324-2 [3026910]
2324-2 [3026910]
6.7e-01
1.1e+00
2.1e+00
—
—
6.5e-01
1.5e-01
cases:26.44%
controls:15.55%
cases:15.87%
controls:5.99%
cases:4.33%
controls:0.53%
—
—
—
—
cases:11.11%
controls:6.12%
cases:13.24%
controls:11.64%
55
322
153
1749
33
124
175
1947
9
11
199
2060
—
—
9
124
72
1903
9
187
59
1420
Prealbumin [Mass/volume] in Serum or Plasma
14338-8 [3013742]
14338-8 [3013742]
1.4e+00
2.4e+00
—
—
—
—
—
cases:5.77%
controls:1.50%
cases:4.81%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
12
31
196
2040
10
9
198
2062
—
—
—
—
—
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
26453-1 [3026361]
1.2e-01
3.3e-01
1.3e+00
2.5e+00
3.7e-01
-7.4e-02
-3.7e-01
cases:34.13%
controls:31.48%
cases:31.73%
controls:25.06%
cases:14.42%
controls:4.49%
cases:2.88%
controls:0.24%
cases:7.95%
controls:5.61%
cases:23.46%
controls:24.81%
cases:25.00%
controls:32.61%
71
652
137
1419
66
519
142
1552
30
93
178
1978
6
5
202
2066
7
116
81
1953
19
503
62
1524
17
524
51
1083
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
20570-8 [3009542]
1.2e-01
3.3e-01
1.3e+00
2.5e+00
3.7e-01
-7.4e-02
-3.7e-01
cases:34.13%
controls:31.48%
cases:31.73%
controls:25.06%
cases:14.42%
controls:4.49%
cases:2.88%
controls:0.24%
cases:7.95%
controls:5.61%
cases:23.46%
controls:24.81%
cases:25.00%
controls:32.61%
71
652
137
1419
66
519
142
1552
30
93
178
1978
6
5
202
2066
7
116
81
1953
19
503
62
1524
17
524
51
1083
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
30428-7 [3024731]
1.2e-01
3.3e-01
1.3e+00
2.5e+00
3.7e-01
-1.4e-01
-3.7e-01
cases:34.13%
controls:31.48%
cases:31.73%
controls:25.06%
cases:14.42%
controls:4.49%
cases:2.88%
controls:0.24%
cases:7.95%
controls:5.61%
cases:22.22%
controls:24.81%
cases:25.00%
controls:32.61%
71
652
137
1419
66
519
142
1552
30
93
178
1978
6
5
202
2066
7
116
81
1953
18
503
63
1524
17
524
51
1083
Platelets [#/volume] in Blood
26515-7 [3007461]
26515-7 [3007461]
1.3e-01
3.3e-01
1.3e+00
2.5e+00
3.7e-01
-7.2e-02
-3.7e-01
cases:34.13%
controls:31.29%
cases:31.73%
controls:25.01%
cases:14.42%
controls:4.49%
cases:2.88%
controls:0.24%
cases:7.95%
controls:5.61%
cases:23.46%
controls:24.77%
cases:25.00%
controls:32.61%
71
648
137
1423
66
518
142
1553
30
93
178
1978
6
5
202
2066
7
116
81
1953
19
502
62
1525
17
524
51
1083
MCH [Entitic mass]
28539-5 [3035941]
28539-5 [3035941]
1.2e-01
3.3e-01
1.3e+00
2.5e+00
3.7e-01
-7.2e-02
-3.7e-01
cases:34.13%
controls:31.39%
cases:31.73%
controls:25.06%
cases:14.42%
controls:4.49%
cases:2.88%
controls:0.24%
cases:7.95%
controls:5.61%
cases:23.46%
controls:24.77%
cases:25.00%
controls:32.61%
71
650
137
1421
66
519
142
1552
30
93
178
1978
6
5
202
2066
7
116
81
1953
19
502
62
1525
17
524
51
1083
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
718-7 [3000963]
1.2e-01
3.3e-01
1.3e+00
2.5e+00
3.7e-01
-7.4e-02
-3.7e-01
cases:34.13%
controls:31.48%
cases:31.73%
controls:25.11%
cases:14.42%
controls:4.49%
cases:2.88%
controls:0.24%
cases:7.95%
controls:5.61%
cases:23.46%
controls:24.81%
cases:25.00%
controls:32.61%
71
652
137
1419
66
520
142
1551
30
93
178
1978
6
5
202
2066
7
116
81
1953
19
503
62
1524
17
524
51
1083
Leukocytes [#/volume] in Blood
26464-8 [3010813]
26464-8 [3010813]
1.2e-01
3.3e-01
1.3e+00
2.5e+00
3.7e-01
-7.4e-02
-3.0e-01
cases:34.13%
controls:31.53%
cases:31.73%
controls:25.06%
cases:14.42%
controls:4.54%
cases:2.88%
controls:0.24%
cases:7.95%
controls:5.61%
cases:23.46%
controls:24.81%
cases:26.47%
controls:32.61%
71
653
137
1418
66
519
142
1552
30
94
178
1977
6
5
202
2066
7
116
81
1953
19
503
62
1524
18
524
50
1083
Transferrin.carbohydrate deficient.disialo/Transferrin.total in Serum or Plasma
21573-1 [3003031]
21573-1 [3003031]
2.0e+00
1.8e+00
—
—
—
—
—
cases:17.31%
controls:2.85%
cases:5.77%
controls:1.01%
—
—
—
—
—
—
—
—
—
—
36
59
172
2012
12
21
196
2050
—
—
—
—
—
Thorax X-ray examination outside radiological department
GD1UA [2001303652]
GD1UA [2001303652]
1.8e+00
—
—
—
—
—
1.9e+00
cases:10.10%
controls:1.88%
—
—
—
—
—
—
—
—
—
—
cases:8.82%
controls:1.49%
21
39
187
2032
—
—
—
—
—
6
24
62
1583
cetirizine; oral
R06AE07 [21603497]
R06AE07 [21603497]
9.7e-01
1.1e+00
—
—
-1.0e+50
1.0e+00
1.5e+00
cases:12.50%
controls:5.12%
cases:8.17%
controls:2.75%
—
—
—
—
cases:0.00%
controls:0.58%
cases:7.41%
controls:2.76%
cases:19.12%
controls:5.04%
26
106
182
1965
17
57
191
2014
—
—
0
12
88
2057
6
56
75
1971
13
81
55
1526
Limited function/disability NOS
A28 [2002000162]
A28 [2002000162]
1.5e+00
2.1e+00
—
—
—
-1.0e+50
—
cases:5.29%
controls:1.26%
cases:7.21%
controls:0.92%
—
—
—
—
—
—
cases:0.00%
controls:0.94%
—
—
11
26
197
2045
15
19
193
2052
—
—
—
0
19
81
2008
—
Outpatient Visit
OP [9202]
OP [9202]
3.7e-01
2.9e-01
9.0e-02
3.6e+00
9.3e-01
5.9e-01
3.4e-01
cases:67.79%
controls:59.34%
cases:46.15%
controls:39.01%
cases:10.58%
controls:9.75%
cases:9.62%
controls:0.29%
cases:15.91%
controls:6.96%
cases:53.09%
controls:38.63%
cases:73.53%
controls:66.33%
141
1229
67
842
96
808
112
1263
22
202
186
1869
20
6
188
2065
14
144
74
1925
43
783
38
1244
50
1066
18
541
Chronic cardiac insufficiency
201 [2001600199]
201 [2001600199]
3.6e+00
—
—
—
1.0e+50
—
—
cases:9.62%
controls:0.29%
—
—
—
—
—
—
cases:6.82%
controls:0.00%
—
—
—
—
20
6
188
2065
—
—
—
6
0
82
2069
—
—
pantoprazole; oral, parenteral
A02BC02 [21600097]
A02BC02 [21600097]
6.9e-01
1.0e+00
1.3e+00
—
1.8e+00
8.3e-01
8.4e-01
cases:23.08%
controls:13.13%
cases:18.27%
controls:7.63%
cases:4.33%
controls:1.16%
—
—
cases:7.95%
controls:1.40%
cases:16.05%
controls:7.70%
cases:29.41%
controls:15.31%
48
272
160
1799
38
158
170
1913
9
24
199
2047
—
7
29
81
2040
13
156
68
1871
20
246
48
1361
Ferritin [Mass/volume] in Serum or Plasma
2276-4 [3001122]
2276-4 [3001122]
7.3e-01
1.1e+00
2.3e+00
—
—
5.7e-01
3.3e-01
cases:12.02%
controls:6.18%
cases:8.17%
controls:2.75%
cases:3.85%
controls:0.39%
—
—
—
—
cases:6.17%
controls:3.60%
cases:7.35%
controls:5.41%
25
128
183
1943
17
57
191
2014
8
8
200
2063
—
—
5
73
76
1954
5
87
63
1520
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]
6768-6 [3035995]
7.6e-01
1.0e+00
1.6e+00
—
1.5e+00
5.0e-01
3.7e-01
cases:28.85%
controls:15.98%
cases:21.15%
controls:8.64%
cases:7.21%
controls:1.55%
—
—
cases:6.82%
controls:1.59%
cases:13.58%
controls:8.73%
cases:20.59%
controls:15.18%
60
331
148
1740
44
179
164
1892
15
32
193
2039
—
6
33
82
2036
11
177
70
1850
14
244
54
1363
Emergency Medicine
93 [38004510]
93 [38004510]
5.5e-01
1.1e+00
2.3e+00
1.0e+50
—
2.1e-01
3.0e-01
cases:19.23%
controls:12.12%
cases:15.38%
controls:5.65%
cases:6.25%
controls:0.68%
cases:8.17%
controls:0.00%
—
—
cases:7.41%
controls:6.07%
cases:16.18%
controls:12.51%
40
251
168
1820
32
117
176
1954
13
14
195
2057
17
0
191
2071
—
6
123
75
1904
11
201
57
1406
Alcohol dependence continuous use
F10.25 [2000501682]
F10.25 [2000501682]
3.4e+00
—
1.0e+50
—
—
—
—
cases:7.69%
controls:0.29%
—
—
cases:2.40%
controls:0.00%
—
—
—
—
—
—
—
—
16
6
192
2065
—
5
0
203
2071
—
—
—
—
Other specified chronic obstructive pulmonary disease
J44.8 [45586673]
J44.8 [45586673]
1.7e+00
1.6e+00
—
—
—
—
—
cases:7.69%
controls:1.55%
cases:5.29%
controls:1.06%
—
—
—
—
—
—
—
—
—
—
16
32
192
2039
11
22
197
2049
—
—
—
—
—
Magnesium [Moles/volume] in Serum or Plasma
2601-3 [3012095]
2601-3 [3012095]
1.4e+00
1.9e+00
—
—
—
—
—
cases:11.54%
controls:3.24%
cases:6.73%
controls:1.11%
—
—
—
—
—
—
—
—
—
—
24
67
184
2004
14
23
194
2048
—
—
—
—
—
Chronic alcohol abuse
P15 [2002000811]
P15 [2002000811]
3.2e+00
—
—
—
—
—
—
cases:6.73%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
—
14
6
194
2065
—
—
—
—
—
—
diazepam; oral, parenteral, rectal
N05BA01 [21604566]
N05BA01 [21604566]
1.5e+00
1.7e+00
—
—
—
—
—
cases:8.17%
controls:1.93%
cases:5.29%
controls:1.01%
—
—
—
—
—
—
—
—
—
—
17
40
191
2031
11
21
197
2050
—
—
—
—
—
Case Management Agency
251B00000X [38004193]
251B00000X [38004193]
2.3e-01
1.4e-01
4.7e-01
3.2e+00
2.4e-01
-2.9e-01
4.4e-01
cases:56.25%
controls:50.56%
cases:46.15%
controls:42.73%
cases:26.44%
controls:18.35%
cases:18.75%
controls:0.97%
cases:20.45%
controls:16.77%
cases:38.27%
controls:45.44%
cases:69.12%
controls:59.12%
117
1047
91
1024
96
885
112
1186
55
380
153
1691
39
20
169
2051
18
347
70
1722
31
921
50
1106
47
950
21
657
quetiapine; oral
N05AH04 [21604544]
N05AH04 [21604544]
1.8e+00
1.3e+00
—
—
—
1.4e+00
—
cases:11.54%
controls:2.03%
cases:5.77%
controls:1.64%
—
—
—
—
—
—
cases:7.41%
controls:1.97%
—
—
24
42
184
2029
12
34
196
2037
—
—
—
6
40
75
1987
—
Fall on same level from slipping, tripping and stumbling
W01 [45756243]
W01 [45756243]
1.4e+00
1.7e+00
—
—
—
—
6.8e-01
cases:12.98%
controls:3.72%
cases:5.29%
controls:0.97%
—
—
—
—
—
—
—
—
cases:7.35%
controls:3.86%
27
77
181
1994
11
20
197
2051
—
—
—
—
5
62
63
1545
Laboratory Visit
OMOP4822461 [32036]
OMOP4822461 [32036]
6.2e-02
1.6e-01
7.5e-01
2.3e+00
5.3e-01
-3.3e-01
-2.8e-01
cases:35.10%
controls:33.70%
cases:33.65%
controls:30.08%
cases:16.35%
controls:8.45%
cases:3.37%
controls:0.34%
cases:14.77%
controls:9.23%
cases:23.46%
controls:29.90%
cases:29.41%
controls:35.47%
73
698
135
1373
70
623
138
1448
34
175
174
1896
7
7
201
2064
13
191
75
1878
19
606
62
1421
20
570
48
1037
Alcohol intoxication UNS
F10.09 [2000501676]
F10.09 [2000501676]
3.0e+00
—
—
—
—
—
—
cases:5.77%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
—
12
6
196
2065
—
—
—
—
—
—
Adjustment and management of cardiac devices
Z45.0 [45595515]
Z45.0 [45595515]
—
—
—
—
—
—
3.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.82%
controls:0.50%
—
—
—
—
—
—
6
8
62
1599
Folate [Moles/volume] in Serum or Plasma
14732-2 [3021960]
14732-2 [3021960]
1.4e+00
1.5e+00
—
—
—
—
-1.0e+50
cases:9.13%
controls:2.41%
cases:5.77%
controls:1.30%
—
—
—
—
—
—
—
—
cases:0.00%
controls:3.17%
19
50
189
2021
12
27
196
2044
—
—
—
—
0
51
68
1556
mirtazapine; oral
N06AX11 [21604740]
N06AX11 [21604740]
1.4e+00
1.4e+00
1.6e+00
—
—
—
7.2e-01
cases:14.42%
controls:4.06%
cases:9.62%
controls:2.46%
cases:3.37%
controls:0.68%
—
—
—
—
—
—
cases:11.76%
controls:6.10%
30
84
178
1987
20
51
188
2020
7
14
201
2057
—
—
—
8
98
60
1509
Supplier / Service Provider
OMOP5117446 [33004]
OMOP5117446 [33004]
-1.5e-01
-3.5e-01
—
—
—
—
2.8e+00
cases:28.37%
controls:31.53%
cases:6.73%
controls:9.27%
—
—
—
—
—
—
—
—
cases:10.29%
controls:0.68%
59
653
149
1418
14
192
194
1879
—
—
—
—
7
11
61
1596
Physiotherapy
R4110 [2001310233]
R4110 [2001310233]
1.1e+00
1.7e+00
—
—
—
—
1.2e+00
cases:10.58%
controls:3.77%
cases:5.77%
controls:1.11%
—
—
—
—
—
—
—
—
cases:8.82%
controls:2.92%
22
78
186
1993
12
23
196
2048
—
—
—
—
6
47
62
1560
Hypo-osmolality and hyponatraemia
E87.1 [45542779]
E87.1 [45542779]
2.7e+00
—
—
—
—
—
—
cases:4.33%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
—
9
6
199
2065
—
—
—
—
—
—
Check up of cardiac pacemaker
XFP20 [2001303367]
XFP20 [2001303367]
1.6e+00
—
-1.0e+50
—
—
—
2.7e+00
cases:3.37%
controls:0.68%
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
cases:8.82%
controls:0.62%
7
14
201
2057
—
0
6
208
2065
—
—
—
6
10
62
1597
SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection
94500-6 [706163]
94500-6 [706163]
1.5e-01
3.1e-01
—
—
2.7e+00
—
—
cases:12.50%
controls:10.96%
cases:6.73%
controls:5.02%
—
—
—
—
cases:6.82%
controls:0.48%
—
—
—
—
26
227
182
1844
14
104
194
1967
—
—
6
10
82
2059
—
—
Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1920-8 [3013721]
1920-8 [3013721]
1.2e+00
1.5e+00
—
—
-1.0e+50
9.8e-01
—
cases:17.79%
controls:6.18%
cases:9.62%
controls:2.32%
—
—
—
—
cases:0.00%
controls:0.24%
cases:6.17%
controls:2.42%
—
—
37
128
171
1943
20
48
188
2023
—
—
0
5
88
2064
5
49
76
1978
—
Bacteria identified in Blood by Culture
600-7 [3023368]
600-7 [3023368]
1.1e+00
1.5e+00
—
—
—
—
—
cases:12.98%
controls:4.88%
cases:7.21%
controls:1.64%
—
—
—
—
—
—
—
—
—
—
27
101
181
1970
15
34
193
2037
—
—
—
—
—
Cathetrisation of vein
TPH04 [2001309597]
TPH04 [2001309597]
1.0e+00
1.5e+00
—
—
—
-1.0e+50
—
cases:8.17%
controls:3.14%
cases:4.33%
controls:0.97%
—
—
—
—
—
—
cases:0.00%
controls:0.74%
—
—
17
65
191
2006
9
20
199
2051
—
—
—
0
15
81
2012
—
Alcohol dependence syndrome, Other and unspecified alcohol dependence
3039X [2000402887]
3039X [2000402887]
2.5e+00
—
—
—
—
—
—
cases:2.88%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
—
6
5
202
2066
—
—
—
—
—
—
Other and unspecified convulsions
R56.8 [45602033]
R56.8 [45602033]
2.5e+00
—
—
—
—
—
—
cases:4.33%
controls:0.39%
—
—
—
—
—
—
—
—
—
—
—
—
9
8
199
2063
—
—
—
—
—
—
Troponin I.cardiac [Mass/volume] in Serum or Plasma
10839-9 [3021337]
10839-9 [3021337]
1.0e+00
1.4e+00
—
—
—
—
1.2e+00
cases:10.58%
controls:4.01%
cases:5.29%
controls:1.35%
—
—
—
—
—
—
—
—
cases:7.35%
controls:2.36%
22
83
186
1988
11
28
197
2043
—
—
—
—
5
38
63
1569
Transferrin receptor.soluble [Mass/volume] in Serum or Plasma
30248-9 [3015399]
30248-9 [3015399]
1.0e+00
1.4e+00
—
—
—
—
1.1e+00
cases:8.65%
controls:3.33%
cases:4.81%
controls:1.21%
—
—
—
—
—
—
—
—
cases:7.35%
controls:2.61%
18
69
190
2002
10
25
198
2046
—
—
—
—
5
42
63
1565
Creatine kinase [Enzymatic activity/volume] in Serum or Plasma
2157-6 [3007220]
2157-6 [3007220]
1.0e+00
1.3e+00
—
—
—
—
—
cases:13.94%
controls:5.50%
cases:5.29%
controls:1.45%
—
—
—
—
—
—
—
—
—
—
29
114
179
1957
11
30
197
2041
—
—
—
—
—
Hepatitis A virus IgM Ab [Presence] in Serum
22314-9 [3013327]
22314-9 [3013327]
2.3e+00
—
—
—
—
—
—
cases:2.88%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
—
6
6
202
2065
—
—
—
—
—
—
Revision of wound of skin of lower limb
QDB05 [2001309969]
QDB05 [2001309969]
2.3e+00
—
—
—
—
—
-1.0e+50
cases:2.88%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
6
6
202
2065
—
—
—
—
—
0
6
68
1601
Ethanol [Moles/volume] in Serum or Plasma
14719-9 [3020191]
14719-9 [3020191]
2.3e+00
—
—
—
—
—
—
cases:2.88%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
—
6
6
202
2065
—
—
—
—
—
—
Albumin [Mass/volume] in Serum or Plasma
1751-7 [3024561]
1751-7 [3024561]
8.2e-01
1.5e+00
1.1e+00
—
—
8.9e-01
1.1e-02
cases:16.83%
controls:8.21%
cases:12.98%
controls:3.38%
cases:2.40%
controls:0.82%
—
—
—
—
cases:9.88%
controls:4.29%
cases:7.35%
controls:7.28%
35
170
173
1901
27
70
181
2001
5
17
203
2054
—
—
8
87
73
1940
5
117
63
1490
Extensive structural and functional ultrasound examination of heart
FM1EE [2001303307]
FM1EE [2001303307]
3.0e-01
1.5e+00
—
1.0e+50
-1.0e+50
2.3e+00
1.4e+00
cases:4.81%
controls:3.62%
cases:3.85%
controls:0.92%
—
—
cases:4.33%
controls:0.00%
cases:0.00%
controls:0.29%
cases:11.11%
controls:1.28%
cases:10.29%
controls:2.68%
10
75
198
1996
8
19
200
2052
—
9
0
199
2071
0
6
88
2063
9
26
72
2001
7
43
61
1564
Thorax X-ray examination
GD1AA [2001303617]
GD1AA [2001303617]
9.3e-01
1.3e+00
—
—
—
1.5e+00
7.2e-01
cases:13.46%
controls:5.79%
cases:8.17%
controls:2.32%
—
—
—
—
—
—
cases:9.88%
controls:2.47%
cases:13.24%
controls:6.91%
28
120
180
1951
17
48
191
2023
—
—
—
8
50
73
1977
9
111
59
1496
perindopril; oral
C09AA04 [21601788]
C09AA04 [21601788]
—
—
—
—
—
—
2.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.35%
controls:0.87%
—
—
—
—
—
—
5
14
63
1593
Office Visit
OMOP4822458 [581477]
OMOP4822458 [581477]
6.2e-01
6.2e-01
2.2e+00
—
—
—
4.6e-01
cases:10.58%
controls:5.99%
cases:3.37%
controls:1.83%
cases:2.88%
controls:0.34%
—
—
—
—
—
—
cases:11.76%
controls:7.78%
22
124
186
1947
7
38
201
2033
6
7
202
2064
—
—
—
8
125
60
1482
Severe depressive episode without psychotic symptoms
F32.2 [45557202]
F32.2 [45557202]
2.2e+00
—
—
—
—
—
—
cases:2.88%
controls:0.34%
—
—
—
—
—
—
—
—
—
—
—
—
6
7
202
2064
—
—
—
—
—
—
Occupational therapy
R4120 [2001310234]
R4120 [2001310234]
2.2e+00
—
—
—
—
—
—
cases:2.88%
controls:0.34%
—
—
—
—
—
—
—
—
—
—
—
—
6
7
202
2064
—
—
—
—
—
—
Thorax extensive CT-examination
GD1BD [2001303621]
GD1BD [2001303621]
2.2e+00
-1.0e+50
—
—
—
—
-1.0e+50
cases:2.88%
controls:0.34%
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
6
7
202
2064
0
5
208
2066
—
—
—
—
0
5
68
1602
Leukocytes [#/volume] in Urine
30405-5 [3018095]
30405-5 [3018095]
6.2e-01
6.7e-01
2.2e+00
—
—
7.8e-01
5.2e-01
cases:10.10%
controls:5.70%
cases:5.77%
controls:3.04%
cases:2.88%
controls:0.34%
—
—
—
—
cases:7.41%
controls:3.55%
cases:10.29%
controls:6.41%
21
118
187
1953
12
63
196
2008
6
7
202
2064
—
—
6
72
75
1955
7
103
61
1504
Oxygen [Partial pressure] in Venous blood
2705-2 [3024354]
2705-2 [3024354]
2.2e+00
—
—
—
—
—
—
cases:6.73%
controls:0.82%
—
—
—
—
—
—
—
—
—
—
—
—
14
17
194
2054
—
—
—
—
—
—
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]
30385-9 [3002385]
5.0e-01
6.9e-01
1.5e+00
—
6.8e-01
1.7e-01
9.9e-02
cases:29.33%
controls:20.09%
cases:26.44%
controls:15.31%
cases:12.02%
controls:3.09%
—
—
cases:6.82%
controls:3.58%
cases:17.28%
controls:15.00%
cases:22.06%
controls:20.41%
61
416
147
1655
55
317
153
1754
25
64
183
2007
—
6
74
82
1995
14
304
67
1723
15
328
53
1279
Bacteria [#/volume] in Urine by Automated count
51480-2 [3031040]
51480-2 [3031040]
3.5e-01
6.9e-01
2.1e+00
—
—
5.9e-01
-2.4e-02
cases:14.42%
controls:10.57%
cases:9.62%
controls:5.07%
cases:4.33%
controls:0.53%
—
—
—
—
cases:8.64%
controls:4.98%
cases:10.29%
controls:10.52%
30
219
178
1852
20
105
188
1966
9
11
199
2060
—
—
7
101
74
1926
7
169
61
1438
dapagliflozin; oral
A10BK01 [1123890]
A10BK01 [1123890]
—
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:10.29%
controls:1.37%
—
—
—
—
—
—
7
22
61
1585
Melaena
K92.1 [45533624]
K92.1 [45533624]
2.1e+00
—
—
—
—
—
-1.0e+50
cases:3.85%
controls:0.48%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
8
10
200
2061
—
—
—
—
—
0
10
68
1597
SARS-CoV-2 (COVID-19) RNA [Presence] in Nasopharynx by NAA with probe detection
94759-8 [586526]
94759-8 [586526]
2.1e+00
—
—
—
—
—
-1.0e+50
cases:3.85%
controls:0.48%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
8
10
200
2061
—
—
—
—
—
0
6
68
1601
12 lead EKG panel
34534-8 [3044889]
34534-8 [3044889]
5.2e-01
3.9e-01
2.1e+00
—
—
3.1e-01
2.0e-01
cases:23.08%
controls:15.16%
cases:11.06%
controls:7.77%
cases:4.81%
controls:0.63%
—
—
—
—
cases:9.88%
controls:7.45%
cases:16.18%
controls:13.63%
48
314
160
1757
23
161
185
1910
10
13
198
2058
—
—
8
151
73
1876
11
219
57
1388
No disease
A97 [2002000230]
A97 [2002000230]
7.0e-01
2.1e+00
—
—
—
-1.0e+50
—
cases:2.88%
controls:1.45%
cases:3.37%
controls:0.43%
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
6
30
202
2041
7
9
201
2062
—
—
—
0
11
81
2016
—
Cardiac dysrhythmias, Atrial fibrillation and flutter
4273A [2000403694]
4273A [2000403694]
2.1e+00
—
—
—
—
—
—
cases:3.37%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
—
—
7
9
201
2062
—
—
—
—
—
—
allopurinol; oral, parenteral
M04AA01 [21604131]
M04AA01 [21604131]
1.0e+00
1.1e+00
1.4e+00
—
—
1.0e+00
1.3e+00
cases:8.65%
controls:3.38%
cases:7.21%
controls:2.61%
cases:2.40%
controls:0.63%
—
—
—
—
cases:7.41%
controls:2.86%
cases:14.71%
controls:4.60%
18
70
190
2001
15
54
193
2017
5
13
203
2058
—
—
6
58
75
1969
10
74
58
1533
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]
62238-1 [40764999]
3.8e-01
5.7e-01
1.5e+00
—
8.6e-01
9.9e-02
-2.0e-01
cases:29.33%
controls:22.07%
cases:26.92%
controls:17.19%
cases:12.02%
controls:2.99%
—
—
cases:9.09%
controls:4.06%
cases:18.52%
controls:17.07%
cases:17.65%
controls:20.72%
61
457
147
1614
56
356
152
1715
25
62
183
2009
—
8
84
80
1985
15
346
66
1681
12
333
56
1274
Cytomegalovirus IgM Ab [Units/volume] in Serum or Plasma
7853-5 [3015635]
7853-5 [3015635]
2.0e+00
—
—
—
—
—
-1.0e+50
cases:2.88%
controls:0.39%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
6
8
202
2063
—
—
—
—
—
0
7
68
1600
Cytomegalovirus IgG Ab [Units/volume] in Serum or Plasma
7852-7 [3010130]
7852-7 [3010130]
2.0e+00
—
—
—
—
—
-1.0e+50
cases:2.88%
controls:0.39%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
6
8
202
2063
—
—
—
—
—
0
7
68
1600
Cytomegalovirus IgG Ab [Titer] in Serum or Plasma
22246-3 [3017918]
22246-3 [3017918]
2.0e+00
—
—
—
—
—
-1.0e+50
cases:2.88%
controls:0.39%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.50%
6
8
202
2063
—
—
—
—
—
0
8
68
1599
Cardiodefibrillation
TFP20 [2001303224]
TFP20 [2001303224]
1.9e+00
—
—
—
—
—
—
cases:5.29%
controls:0.82%
—
—
—
—
—
—
—
—
—
—
—
—
11
17
197
2054
—
—
—
—
—
—
Bicarbonate [Moles/volume] standard in Venous blood
19232-8 [3007628]
19232-8 [3007628]
1.9e+00
—
—
—
—
—
—
cases:5.29%
controls:0.82%
—
—
—
—
—
—
—
—
—
—
—
—
11
17
197
2054
—
—
—
—
—
—
Bicarbonate [Moles/volume] standard in Arterial blood
19230-2 [3014218]
19230-2 [3014218]
1.9e+00
—
—
—
—
-1.0e+50
—
cases:6.73%
controls:1.11%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
14
23
194
2048
—
—
—
—
0
7
81
2020
—
Influenza virus A RNA [Presence] in Specimen by NAA with probe detection
34487-9 [3044938]
34487-9 [3044938]
9.5e-01
1.8e+00
—
—
—
—
—
cases:5.77%
controls:2.32%
cases:3.85%
controls:0.63%
—
—
—
—
—
—
—
—
—
—
12
48
196
2023
8
13
200
2058
—
—
—
—
—
INR in Blood by Coagulation assay
34714-6 [3032080]
34714-6 [3032080]
8.2e-01
1.0e+00
1.0e+00
—
—
7.9e-01
5.9e-01
cases:19.71%
controls:9.75%
cases:11.54%
controls:4.49%
cases:3.85%
controls:1.40%
—
—
—
—
cases:9.88%
controls:4.74%
cases:13.24%
controls:7.78%
41
202
167
1869
24
93
184
1978
8
29
200
2042
—
—
8
96
73
1931
9
125
59
1482
Monitored bed care
WX892 [2001310850]
WX892 [2001310850]
1.8e+00
—
—
—
—
—
—
cases:4.81%
controls:0.82%
—
—
—
—
—
—
—
—
—
—
—
—
10
17
198
2054
—
—
—
—
—
—
Transferrin [Mass/volume] in Serum or Plasma
3034-6 [3004789]
3034-6 [3004789]
1.8e+00
7.0e-01
2.1e+00
—
—
—
1.2e+00
cases:10.58%
controls:1.93%
cases:2.88%
controls:1.45%
cases:2.40%
controls:0.29%
—
—
—
—
—
—
cases:7.35%
controls:2.43%
22
40
186
2031
6
30
202
2041
5
6
203
2065
—
—
—
5
39
63
1568
hydroxyzine; oral, parenteral
N05BB01 [21604590]
N05BB01 [21604590]
1.8e+00
—
—
—
—
—
-1.0e+50
cases:5.77%
controls:1.01%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.18%
12
21
196
2050
—
—
—
—
—
0
19
68
1588
amiodarone; oral, parenteral
C01BD01 [21600270]
C01BD01 [21600270]
1.8e+00
—
—
—
—
—
—
cases:3.37%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
—
—
7
12
201
2059
—
—
—
—
—
—
Myoglobin [Mass/volume] in Serum or Plasma
2639-3 [3005895]
2639-3 [3005895]
1.8e+00
—
—
—
—
-1.0e+50
-1.0e+50
cases:3.85%
controls:0.68%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.25%
cases:0.00%
controls:0.50%
8
14
200
2057
—
—
—
—
0
5
81
2022
0
8
68
1599
Lactate [Moles/volume] in Serum or Plasma
2524-7 [3014111]
2524-7 [3014111]
1.8e+00
—
—
—
—
—
—
cases:8.65%
controls:1.59%
—
—
—
—
—
—
—
—
—
—
—
—
18
33
190
2038
—
—
—
—
—
—
Limited function/disability (L)
L28 [2002000647]
L28 [2002000647]
1.7e+00
1.4e+00
—
—
—
-1.0e+50
—
cases:5.29%
controls:0.97%
cases:2.40%
controls:0.63%
—
—
—
—
—
—
cases:0.00%
controls:0.89%
—
—
11
20
197
2051
5
13
203
2058
—
—
—
0
18
81
2009
—
omeprazole; oral, parenteral
A02BC01 [21600096]
A02BC01 [21600096]
4.3e-01
8.0e-01
—
—
—
1.7e+00
3.4e-01
cases:4.33%
controls:2.85%
cases:3.37%
controls:1.55%
—
—
—
—
—
—
cases:8.64%
controls:1.63%
cases:7.35%
controls:5.35%
9
59
199
2012
7
32
201
2039
—
—
—
7
33
74
1994
5
86
63
1521
Depressive episode, unspecified
F32.9 [45571760]
F32.9 [45571760]
1.7e+00
—
—
—
—
—
—
cases:5.77%
controls:1.06%
—
—
—
—
—
—
—
—
—
—
—
—
12
22
196
2049
—
—
—
—
—
—
Carbon dioxide [Partial pressure] in Venous blood
2021-4 [3021447]
2021-4 [3021447]
1.7e+00
8.8e-01
—
—
—
—
1.3e+00
cases:6.73%
controls:1.30%
cases:2.40%
controls:1.01%
—
—
—
—
—
—
—
—
cases:7.35%
controls:2.05%
14
27
194
2044
5
21
203
2050
—
—
—
—
5
33
63
1574
Base excess in Venous blood by calculation
1927-3 [3002032]
1927-3 [3002032]
1.7e+00
8.8e-01
—
—
—
—
1.3e+00
cases:6.73%
controls:1.30%
cases:2.40%
controls:1.01%
—
—
—
—
—
—
—
—
cases:7.35%
controls:2.12%
14
27
194
2044
5
21
203
2050
—
—
—
—
5
34
63
1573
Dizziness and giddiness
R42 [45568132]
R42 [45568132]
1.7e+00
—
—
—
—
-1.0e+50
—
cases:5.29%
controls:1.01%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
11
21
197
2050
—
—
—
—
0
11
81
2016
—
Normoblasts [#/volume] in Blood
715-3 [3021589]
715-3 [3021589]
9.0e-01
7.8e-01
1.1e+00
—
—
9.1e-02
3.9e-01
cases:17.79%
controls:8.06%
cases:12.98%
controls:6.37%
cases:3.85%
controls:1.35%
—
—
—
—
cases:7.41%
controls:6.81%
cases:11.76%
controls:8.28%
37
167
171
1904
27
132
181
1939
8
28
200
2043
—
—
6
138
75
1889
8
133
60
1474
Iron [Moles/volume] in Serum or Plasma
14798-3 [3022948]
14798-3 [3022948]
1.7e+00
6.7e-01
—
—
—
—
1.1e+00
cases:9.62%
controls:1.93%
cases:2.88%
controls:1.50%
—
—
—
—
—
—
—
—
cases:7.35%
controls:2.49%
20
40
188
2031
6
31
202
2040
—
—
—
—
5
40
63
1567
Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]
2951-2 [3019550]
3.0e-01
5.0e-01
1.6e+00
—
9.2e-01
-6.0e-02
-1.1e-01
cases:33.17%
controls:26.80%
cases:29.33%
controls:20.04%
cases:13.46%
controls:2.95%
—
—
cases:10.23%
controls:4.35%
cases:18.52%
controls:19.44%
cases:26.47%
controls:28.62%
69
555
139
1516
61
415
147
1656
28
61
180
2010
—
9
90
79
1979
15
394
66
1633
18
460
50
1147
pH of Venous blood
2746-6 [3012544]
2746-6 [3012544]
1.6e+00
—
—
—
—
—
1.3e+00
cases:6.73%
controls:1.40%
—
—
—
—
—
—
—
—
—
—
cases:7.35%
controls:2.18%
14
29
194
2042
—
—
—
—
—
5
35
63
1572
Basophils/Leukocytes in Blood
30180-4 [3022096]
30180-4 [3022096]
7.2e-01
8.9e-01
1.2e+00
—
—
—
-8.7e-02
cases:15.38%
controls:8.16%
cases:10.10%
controls:4.39%
cases:2.88%
controls:0.87%
—
—
—
—
—
—
cases:7.35%
controls:7.97%
32
169
176
1902
21
91
187
1980
6
18
202
2053
—
—
—
5
128
63
1479
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
2823-3 [3023103]
2.9e-01
5.1e-01
1.6e+00
—
1.0e+00
5.3e-02
-1.1e-01
cases:33.17%
controls:27.14%
cases:29.81%
controls:20.28%
cases:13.46%
controls:3.04%
—
—
cases:11.36%
controls:4.35%
cases:20.99%
controls:20.13%
cases:26.47%
controls:28.69%
69
562
139
1509
62
420
146
1651
28
63
180
2008
—
10
90
78
1979
17
408
64
1619
18
461
50
1146
melatonin; oral
N05CH01 [21604659]
N05CH01 [21604659]
1.6e+00
1.6e+00
—
—
-1.0e+50
—
-1.0e+50
cases:7.21%
controls:1.55%
cases:3.37%
controls:0.68%
—
—
—
—
cases:0.00%
controls:0.24%
—
—
cases:0.00%
controls:1.80%
15
32
193
2039
7
14
201
2057
—
—
0
5
88
2064
—
0
29
68
1578
Monocytes/Leukocytes in Blood
26485-3 [3019069]
26485-3 [3019069]
7.0e-01
8.9e-01
1.2e+00
—
—
—
1.5e-01
cases:15.38%
controls:8.26%
cases:10.10%
controls:4.39%
cases:2.88%
controls:0.92%
—
—
—
—
—
—
cases:8.82%
controls:7.72%
32
171
176
1900
21
91
187
1980
6
19
202
2052
—
—
—
6
124
62
1483
Eosinophils/Leukocytes in Blood
26450-7 [3006504]
26450-7 [3006504]
7.0e-01
8.9e-01
1.2e+00
—
—
—
1.3e-01
cases:15.38%
controls:8.26%
cases:10.10%
controls:4.39%
cases:2.88%
controls:0.87%
—
—
—
—
—
—
cases:8.82%
controls:7.84%
32
171
176
1900
21
91
187
1980
6
18
202
2053
—
—
—
6
126
62
1481
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]
28540-3 [3003338]
1.8e-01
3.8e-01
1.5e+00
—
6.5e-01
8.9e-02
-1.1e-01
cases:27.40%
controls:23.95%
cases:23.56%
controls:17.38%
cases:12.50%
controls:3.09%
—
—
cases:6.82%
controls:3.67%
cases:18.52%
controls:17.22%
cases:22.06%
controls:23.96%
57
496
151
1575
49
360
159
1711
26
64
182
2007
—
6
76
82
1993
15
349
66
1678
15
385
53
1222
Bilirubin.conjugated [Moles/volume] in Serum or Plasma
29760-6 [3005772]
29760-6 [3005772]
1.5e+00
1.2e+00
—
—
—
—
-1.0e+50
cases:9.13%
controls:2.22%
cases:3.85%
controls:1.16%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.43%
19
46
189
2025
8
24
200
2047
—
—
—
—
0
23
68
1584
Concussion
S06.0 [45582805]
S06.0 [45582805]
1.5e+00
—
—
—
—
-1.0e+50
—
cases:4.33%
controls:1.01%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
9
21
199
2050
—
—
—
—
0
7
81
2020
—
Carbon dioxide [Partial pressure] in Arterial blood
2019-8 [3027946]
2019-8 [3027946]
1.5e+00
—
—
—
—
—
—
cases:8.17%
controls:2.03%
—
—
—
—
—
—
—
—
—
—
—
—
17
42
191
2029
—
—
—
—
—
—
Oxygen [Partial pressure] in Arterial blood
2703-7 [3027801]
2703-7 [3027801]
1.5e+00
—
—
—
—
—
—
cases:8.17%
controls:2.03%
—
—
—
—
—
—
—
—
—
—
—
—
17
42
191
2029
—
—
—
—
—
—
Diabetes, insulin-treated
103 [2001600103]
103 [2001600103]
9.0e-02
—
—
—
—
—
1.5e+00
cases:3.85%
controls:3.52%
—
—
—
—
—
—
—
—
—
—
cases:13.24%
controls:3.42%
8
73
200
1998
—
—
—
—
—
9
55
59
1552
Carboxyhemoglobin/Hemoglobin.total in Arterial blood
2030-5 [3028653]
2030-5 [3028653]
1.4e+00
—
—
—
—
—
—
cases:5.29%
controls:1.30%
—
—
—
—
—
—
—
—
—
—
—
—
11
27
197
2044
—
—
—
—
—
—
Methemoglobin/Hemoglobin.total in Arterial blood
2615-3 [3006217]
2615-3 [3006217]
1.4e+00
—
—
—
—
—
—
cases:5.29%
controls:1.30%
—
—
—
—
—
—
—
—
—
—
—
—
11
27
197
2044
—
—
—
—
—
—
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
14682-9 [3020564]
1.7e-01
3.9e-01
1.4e+00
—
9.9e-01
-1.4e-01
-1.4e-01
cases:33.65%
controls:29.94%
cases:31.25%
controls:23.47%
cases:13.46%
controls:3.57%
—
—
cases:12.50%
controls:5.03%
cases:20.99%
controls:23.43%
cases:27.94%
controls:30.93%
70
620
138
1451
65
486
143
1585
28
74
180
1997
—
11
104
77
1965
17
475
64
1552
19
497
49
1110
Bicarbonate [Moles/volume] in Serum or Plasma
1963-8 [3016293]
1963-8 [3016293]
1.4e+00
—
—
—
—
—
—
cases:5.77%
controls:1.45%
—
—
—
—
—
—
—
—
—
—
—
—
12
30
196
2041
—
—
—
—
—
—
Other and unspecified abdominal pain
R10.4 [45568113]
R10.4 [45568113]
4.3e-01
1.4e+00
—
—
—
—
—
cases:5.77%
controls:3.81%
cases:5.77%
controls:1.45%
—
—
—
—
—
—
—
—
—
—
12
79
196
1992
12
30
196
2041
—
—
—
—
—
Base excess in Arterial blood by calculation
1925-7 [3003396]
1925-7 [3003396]
1.4e+00
—
—
—
—
—
—
cases:8.17%
controls:2.12%
—
—
—
—
—
—
—
—
—
—
—
—
17
44
191
2027
—
—
—
—
—
—
Gas panel - Venous blood
24339-4 [3000991]
24339-4 [3000991]
1.4e+00
9.3e-01
—
—
—
—
—
cases:6.73%
controls:1.74%
cases:2.40%
controls:0.97%
—
—
—
—
—
—
—
—
—
—
14
36
194
2035
5
20
203
2051
—
—
—
—
—
Fractional oxyhemoglobin in Arterial blood
2714-4 [3014007]
2714-4 [3014007]
1.4e+00
—
—
—
—
—
—
cases:5.29%
controls:1.35%
—
—
—
—
—
—
—
—
—
—
—
—
11
28
197
2043
—
—
—
—
—
—
pH of Serum or Plasma
2753-2 [3018418]
2753-2 [3018418]
1.4e+00
8.9e-01
—
—
—
—
5.4e-01
cases:15.87%
controls:4.49%
cases:5.77%
controls:2.46%
—
—
—
—
—
—
—
—
cases:7.35%
controls:4.42%
33
93
175
1978
12
51
196
2020
—
—
—
—
5
71
63
1536
pH of Arterial blood
2744-1 [3019977]
2744-1 [3019977]
1.4e+00
—
—
—
—
—
—
cases:8.17%
controls:2.17%
—
—
—
—
—
—
—
—
—
—
—
—
17
45
191
2026
—
—
—
—
—
—
Pneumonia, unspecified
J18.9 [45601123]
J18.9 [45601123]
1.4e+00
8.9e-01
—
1.0e+50
—
-1.0e+50
—
cases:8.65%
controls:2.37%
cases:2.88%
controls:1.21%
—
—
cases:2.88%
controls:0.00%
—
—
cases:0.00%
controls:1.18%
—
—
18
49
190
2022
6
25
202
2046
—
6
0
202
2071
—
0
24
81
2003
—
pregabalin; oral
N02BF02 [955152]
N02BF02 [955152]
5.9e-01
1.4e+00
—
—
—
—
—
cases:5.77%
controls:3.28%
cases:5.77%
controls:1.55%
—
—
—
—
—
—
—
—
—
—
12
68
196
2003
12
32
196
2039
—
—
—
—
—
Chloride [Moles/volume] in Serum or Plasma
2075-0 [3014576]
2075-0 [3014576]
1.3e+00
7.8e-01
—
—
—
—
—
cases:8.17%
controls:2.32%
cases:2.40%
controls:1.11%
—
—
—
—
—
—
—
—
—
—
17
48
191
2023
5
23
203
2048
—
—
—
—
—
Holo-transcobalamin II [Moles/volume] in Serum
72160-5 [43054903]
72160-5 [43054903]
6.7e-01
1.3e+00
—
—
—
—
—
cases:12.02%
controls:6.52%
cases:9.13%
controls:2.66%
—
—
—
—
—
—
—
—
—
—
25
135
183
1936
19
55
189
2016
—
—
—
—
—
tiotropium bromide; inhalant
R03BB04 [21603296]
R03BB04 [21603296]
1.3e+00
1.0e+00
—
—
—
—
—
cases:5.77%
controls:1.64%
cases:3.37%
controls:1.21%
—
—
—
—
—
—
—
—
—
—
12
34
196
2037
7
25
201
2046
—
—
—
—
—
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1742-6 [3006923]
1742-6 [3006923]
1.4e-01
5.0e-01
1.2e+00
—
8.7e-01
-2.8e-01
-2.1e-01
cases:31.73%
controls:28.73%
cases:29.81%
controls:20.47%
cases:9.13%
controls:2.80%
—
—
cases:7.95%
controls:3.48%
cases:16.05%
controls:20.13%
cases:25.00%
controls:29.06%
66
595
142
1476
62
424
146
1647
19
58
189
2013
—
7
72
81
1997
13
408
68
1619
17
467
51
1140
Oxygen saturation in Arterial blood
2708-6 [3016502]
2708-6 [3016502]
1.2e+00
—
—
—
—
—
—
cases:6.73%
controls:2.03%
—
—
—
—
—
—
—
—
—
—
—
—
14
42
194
2029
—
—
—
—
—
—
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
1988-5 [3020460]
3.4e-01
5.9e-01
1.2e+00
—
9.5e-01
1.3e-01
2.8e-02
cases:30.29%
controls:23.56%
cases:22.60%
controls:13.95%
cases:8.65%
controls:2.66%
—
—
cases:6.82%
controls:2.75%
cases:14.81%
controls:13.22%
cases:23.53%
controls:23.02%
63
488
145
1583
47
289
161
1782
18
55
190
2016
—
6
57
82
2012
12
268
69
1759
16
370
52
1237
Calcium.ionized [Moles/volume] in Serum or Plasma
1995-0 [3021347]
1995-0 [3021347]
1.2e+00
7.7e-01
—
—
—
—
5.1e-01
cases:20.67%
controls:7.10%
cases:7.21%
controls:3.48%
—
—
—
—
—
—
—
—
cases:10.29%
controls:6.47%
43
147
165
1924
15
72
193
1999
—
—
—
—
7
104
61
1503
Dyspnoea
R06.0 [45558449]
R06.0 [45558449]
1.2e+00
7.0e-01
—
—
—
—
—
cases:8.65%
controls:2.70%
cases:2.40%
controls:1.21%
—
—
—
—
—
—
—
—
—
—
18
56
190
2015
5
25
203
2046
—
—
—
—
—
Respiratory and circulatory monitoring
WX700 [2001310817]
WX700 [2001310817]
1.2e+00
—
—
—
—
—
—
cases:6.73%
controls:2.08%
—
—
—
—
—
—
—
—
—
—
—
—
14
43
194
2028
—
—
—
—
—
—
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]
19072-8 [3016431]
1.2e+00
6.8e-01
—
—
—
—
1.0e-01
cases:21.15%
controls:7.44%
cases:7.69%
controls:4.06%
—
—
—
—
—
—
—
—
cases:8.82%
controls:8.03%
44
154
164
1917
16
84
192
1987
—
—
—
—
6
129
62
1478
Bacteria identified in Isolate by Culture
43409-2 [3042936]
43409-2 [3042936]
1.2e+00
—
—
—
—
—
—
cases:8.17%
controls:2.61%
—
—
—
—
—
—
—
—
—
—
—
—
17
54
191
2017
—
—
—
—
—
—
escitalopram; oral
N06AB10 [21604718]
N06AB10 [21604718]
1.2e+00
1.0e+00
—
—
—
—
—
cases:6.73%
controls:2.12%
cases:2.88%
controls:1.06%
—
—
—
—
—
—
—
—
—
—
14
44
194
2027
6
22
202
2049
—
—
—
—
—
clindamycin; oral, parenteral
J01FF01 [21602985]
J01FF01 [21602985]
1.1e+00
—
—
—
—
—
1.3e+00
cases:6.73%
controls:2.37%
—
—
—
—
—
—
—
—
—
—
cases:8.82%
controls:2.49%
14
49
194
2022
—
—
—
—
—
6
40
62
1567
Neurology
13 [38004458]
13 [38004458]
7.0e-01
1.1e+00
1.4e+00
—
—
5.4e-01
1.2e-01
cases:15.38%
controls:8.31%
cases:8.17%
controls:2.95%
cases:2.40%
controls:0.63%
—
—
—
—
cases:7.41%
controls:4.44%
cases:11.76%
controls:10.58%
32
172
176
1899
17
61
191
2010
5
13
203
2058
—
—
6
90
75
1937
8
170
60
1437
Exposure to unspecified factor
X59 [45756412]
X59 [45756412]
1.1e+00
1.7e+00
—
—
—
—
1.3e+00
cases:6.73%
controls:2.41%
cases:2.88%
controls:0.53%
—
—
—
—
—
—
—
—
cases:7.35%
controls:2.18%
14
50
194
2021
6
11
202
2060
—
—
—
—
5
35
63
1572
Phosphate [Moles/volume] in Serum or Plasma
14879-1 [3003458]
14879-1 [3003458]
1.1e+00
—
—
—
—
—
—
cases:7.21%
controls:2.61%
—
—
—
—
—
—
—
—
—
—
—
—
15
54
193
2017
—
—
—
—
—
—
propranolol; oral, parenteral
C07AA05 [21601670]
C07AA05 [21601670]
1.1e+00
1.0e+00
—
—
—
—
—
cases:7.69%
controls:2.80%
cases:4.33%
controls:1.59%
—
—
—
—
—
—
—
—
—
—
16
58
192
2013
9
33
199
2038
—
—
—
—
—
Short blood count panel - Blood
55429-5 [40758558]
55429-5 [40758558]
1.1e+00
7.1e-01
—
—
-1.0e+50
—
—
cases:11.06%
controls:4.15%
cases:3.37%
controls:1.69%
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
23
86
185
1985
7
35
201
2036
—
—
0
5
88
2064
—
—
Troponin T.cardiac [Mass/volume] in Serum or Plasma
6598-7 [3019800]
6598-7 [3019800]
5.6e-01
1.0e+00
—
—
—
—
—
cases:11.54%
controls:6.90%
cases:7.69%
controls:2.90%
—
—
—
—
—
—
—
—
—
—
24
143
184
1928
16
60
192
2011
—
—
—
—
—
enoxaparin; parenteral
B01AB05 [21600976]
B01AB05 [21600976]
1.0e+00
8.8e-01
—
—
—
—
—
cases:8.65%
controls:3.28%
cases:2.40%
controls:1.01%
—
—
—
—
—
—
—
—
—
—
18
68
190
2003
5
21
203
2050
—
—
—
—
—
Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma
48065-7 [3051714]
48065-7 [3051714]
9.9e-01
8.9e-01
—
—
—
—
—
cases:9.62%
controls:3.81%
cases:2.88%
controls:1.21%
—
—
—
—
—
—
—
—
—
—
20
79
188
1992
6
25
202
2046
—
—
—
—
—
Pharmacy visit
OMOP4822462 [581458]
OMOP4822462 [581458]
3.6e-01
5.5e-01
3.2e-01
9.0e-01
9.4e-01
5.6e-01
9.7e-01
cases:88.46%
controls:84.21%
cases:85.58%
controls:77.40%
cases:48.56%
controls:40.56%
cases:3.85%
controls:1.59%
cases:64.77%
controls:41.90%
cases:87.65%
controls:80.17%
cases:97.06%
controls:92.59%
184
1744
24
327
178
1603
30
468
101
840
107
1231
8
33
200
2038
57
867
31
1202
71
1625
10
402
66
1488
2
119
Neutrophils/Leukocytes in Blood
26511-6 [3018010]
26511-6 [3018010]
6.9e-01
9.3e-01
1.3e+00
—
—
—
-6.9e-02
cases:15.38%
controls:8.35%
cases:10.10%
controls:4.25%
cases:2.88%
controls:0.77%
—
—
—
—
—
—
cases:7.35%
controls:7.84%
32
173
176
1898
21
88
187
1983
6
16
202
2055
—
—
—
5
126
63
1481
Amylase [Enzymatic activity/volume] in Serum or Plasma
1798-8 [3016771]
1798-8 [3016771]
8.6e-01
1.1e+00
—
—
-1.0e+50
—
4.8e-01
cases:11.54%
controls:5.21%
cases:5.29%
controls:1.83%
—
—
—
—
cases:0.00%
controls:0.24%
—
—
cases:7.35%
controls:4.67%
24
108
184
1963
11
38
197
2033
—
—
0
5
88
2064
—
5
75
63
1532
Neutrophils [#/volume] in Blood by Automated count
751-8 [3013650]
751-8 [3013650]
8.4e-01
7.7e-01
1.1e+00
—
—
—
-4.0e-02
cases:20.67%
controls:10.14%
cases:11.06%
controls:5.46%
cases:3.85%
controls:1.35%
—
—
—
—
—
—
cases:8.82%
controls:9.15%
43
210
165
1861
23
113
185
1958
8
28
200
2043
—
—
—
6
147
62
1460
Thyrotropin [Units/volume] in Serum or Plasma
3016-3 [3009201]
3016-3 [3009201]
1.4e-01
7.3e-01
—
—
—
-3.5e-01
1.2e-01
cases:22.12%
controls:19.75%
cases:18.75%
controls:10.04%
—
—
—
—
—
—
cases:7.41%
controls:10.16%
cases:20.59%
controls:18.67%
46
409
162
1662
39
208
169
1863
—
—
—
6
206
75
1821
14
300
54
1307
Basophils [#/volume] in Blood
26444-0 [3006315]
26444-0 [3006315]
7.2e-01
7.9e-01
1.1e+00
—
—
—
7.0e-02
cases:15.87%
controls:8.40%
cases:9.62%
controls:4.59%
cases:2.88%
controls:1.01%
—
—
—
—
—
—
cases:8.82%
controls:8.28%
33
174
175
1897
20
95
188
1976
6
21
202
2050
—
—
—
6
133
62
1474
Monocytes [#/volume] in Blood
26484-6 [3001604]
26484-6 [3001604]
7.1e-01
7.9e-01
1.1e+00
—
—
—
7.8e-02
cases:15.87%
controls:8.45%
cases:9.62%
controls:4.59%
cases:2.88%
controls:0.97%
—
—
—
—
—
—
cases:8.82%
controls:8.21%
33
175
175
1896
20
95
188
1976
6
20
202
2051
—
—
—
6
132
62
1475
Lymphocytes [#/volume] in Blood
26474-7 [3019198]
26474-7 [3019198]
7.0e-01
7.2e-01
1.0e+00
—
—
—
7.0e-02
cases:16.35%
controls:8.84%
cases:9.62%
controls:4.93%
cases:2.88%
controls:1.06%
—
—
—
—
—
—
cases:8.82%
controls:8.28%
34
183
174
1888
20
102
188
1969
6
22
202
2049
—
—
—
6
133
62
1474
Lymphocytes/Leukocytes in Blood
26478-8 [3002030]
26478-8 [3002030]
7.0e-01
8.5e-01
1.2e+00
—
—
—
1.1e-01
cases:15.87%
controls:8.59%
cases:10.10%
controls:4.59%
cases:2.88%
controls:0.92%
—
—
—
—
—
—
cases:8.82%
controls:7.97%
33
178
175
1893
21
95
187
1976
6
19
202
2052
—
—
—
6
128
62
1479
Glucose [Moles/volume] in Serum or Plasma
14749-6 [3013826]
14749-6 [3013826]
6.2e-01
6.4e-01
1.6e+00
—
—
3.0e-01
-5.4e-02
cases:21.15%
controls:12.60%
cases:8.65%
controls:4.78%
cases:2.40%
controls:0.48%
—
—
—
—
cases:6.17%
controls:4.64%
cases:8.82%
controls:9.27%
44
261
164
1810
18
99
190
1972
5
10
203
2061
—
—
5
94
76
1933
6
149
62
1458
Outpatient Hospital
22 [8756]
22 [8756]
6.2e-01
6.9e-01
1.0e+00
1.0e+50
—
1.1e+00
7.9e-01
cases:32.21%
controls:20.42%
cases:11.06%
controls:5.89%
cases:2.40%
controls:0.87%
cases:9.62%
controls:0.00%
—
—
cases:14.81%
controls:5.57%
cases:38.24%
controls:21.97%
67
423
141
1648
23
122
185
1949
5
18
203
2053
20
0
188
2071
—
12
113
69
1914
26
353
42
1254
cefalexin; oral
J01DB01 [21602870]
J01DB01 [21602870]
5.5e-01
5.8e-01
9.8e-01
—
—
6.7e-01
-2.0e-01
cases:33.17%
controls:22.31%
cases:12.50%
controls:7.44%
cases:2.40%
controls:0.92%
—
—
—
—
cases:14.81%
controls:8.19%
cases:22.06%
controls:25.76%
69
462
139
1609
26
154
182
1917
5
19
203
2052
—
—
12
166
69
1861
15
414
53
1193
hydrocortisone buteprate
D07AB11 [21602115]
D07AB11 [21602115]
3.9e-01
7.8e-01
—
—
-1.0e+50
—
9.2e-01
cases:9.13%
controls:6.37%
cases:4.81%
controls:2.27%
—
—
—
—
cases:0.00%
controls:0.34%
—
—
cases:14.71%
controls:6.41%
19
132
189
1939
10
47
198
2024
—
—
0
7
88
2062
—
10
103
58
1504
Ingrowing nail
L60.0 [45548199]
L60.0 [45548199]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
0
7
68
1600
testosterone; oral, parenteral, rectal, sublingual, transdermal
G03BA03 [21602510]
G03BA03 [21602510]
—
-1.0e+50
-1.0e+50
—
-1.0e+50
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:0.97%
cases:0.00%
controls:0.39%
—
—
cases:0.00%
controls:0.24%
cases:0.00%
controls:1.13%
cases:0.00%
controls:1.43%
—
0
20
208
2051
0
8
208
2063
—
0
5
88
2064
0
23
81
2004
0
23
68
1584
boric acid
S02AA03 [21605149]
S02AA03 [21605149]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
cases:0.00%
controls:0.37%
—
—
—
—
—
0
9
81
2018
0
6
68
1601
Extended examination of mouth
SAA03 [2001310276]
SAA03 [2001310276]
3.5e-01
-1.0e+50
—
—
—
—
8.9e-01
cases:4.81%
controls:3.43%
cases:0.00%
controls:1.11%
—
—
—
—
—
—
—
—
cases:10.29%
controls:4.48%
10
71
198
2000
0
23
208
2048
—
—
—
—
7
72
61
1535
Counselling and guidance which enhance independent living
R2130 [2001310196]
R2130 [2001310196]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
0
10
81
2017
—
Laparoscopic cholecystectomy
JKA21 [2001305294]
JKA21 [2001305294]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.82%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.30%
cases:0.00%
controls:0.62%
0
17
208
2054
—
—
—
—
0
6
81
2021
0
10
68
1597
Fasting glucose [Moles/volume] in Serum or Plasma
14771-0 [3018251]
14771-0 [3018251]
1.2e-01
3.9e-01
1.2e+00
—
—
-4.3e-01
-1.7e-01
cases:26.44%
controls:24.19%
cases:18.75%
controls:13.57%
cases:3.85%
controls:1.16%
—
—
—
—
cases:8.64%
controls:12.73%
cases:20.59%
controls:23.52%
55
501
153
1570
39
281
169
1790
8
24
200
2047
—
—
7
258
74
1769
14
378
54
1229
Retinal detachment with retinal break
H33.0 [45547857]
H33.0 [45547857]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
208
2064
—
—
—
—
—
—
Procalcitonin [Mass/volume] in Serum or Plasma
33959-8 [3046279]
33959-8 [3046279]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
cases:0.00%
controls:0.62%
—
—
—
—
—
0
10
81
2017
0
10
68
1597
Influenza virus A Ag [Presence] in Specimen
31859-2 [3002523]
31859-2 [3002523]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
208
2066
—
—
—
—
—
—
pseudoephedrine, combinations; oral
R01BA52 [21603213]
R01BA52 [21603213]
-1.9e-01
—
-1.0e+50
—
—
-1.0e+50
—
cases:6.25%
controls:7.44%
—
—
cases:0.00%
controls:0.34%
—
—
—
—
cases:0.00%
controls:2.57%
—
—
13
154
195
1917
—
0
7
208
2064
—
—
0
52
81
1975
—
Very extensive body CT
JN4CD [2001310902]
JN4CD [2001310902]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
208
2063
—
—
—
—
—
—
Unstable angina
I20.00 [2000502384]
I20.00 [2000502384]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.34%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
0
7
208
2064
—
—
—
—
—
0
5
68
1602
Other cerebral infarction
I63.8 [45605810]
I63.8 [45605810]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
0
5
68
1602
Puncture of vitreous body with injection of medication
CKD05 [2001301407]
CKD05 [2001301407]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
cases:0.00%
controls:0.30%
cases:0.00%
controls:0.68%
—
0
6
208
2065
—
—
—
0
6
81
2021
0
11
68
1596
azithromycin; oral, parenteral
J01FA10 [21602978]
J01FA10 [21602978]
-3.1e-01
5.5e-01
—
—
—
—
—
cases:4.81%
controls:6.47%
cases:2.88%
controls:1.69%
—
—
—
—
—
—
—
—
—
—
10
134
198
1937
6
35
202
2036
—
—
—
—
—
Asthma
J45 [45596282]
J45 [45596282]
7.4e-01
—
—
—
—
—
—
cases:2.88%
controls:1.40%
—
—
—
—
—
—
—
—
—
—
—
—
6
29
202
2042
—
—
—
—
—
—
dexamethasone
D10AA03 [21602286]
D10AA03 [21602286]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
cases:0.00%
controls:0.59%
cases:0.00%
controls:1.31%
—
0
5
208
2066
—
—
—
0
12
81
2015
0
21
68
1586
Essential hypertension, Unspecified
4019X [2000403546]
4019X [2000403546]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
208
2062
—
—
—
—
—
—
Secondary malignant neoplasm of other specified sites
C79.8 [45547524]
C79.8 [45547524]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
208
2066
—
—
—
—
—
—
Femoral plexus blockade
WX212 [2001310782]
WX212 [2001310782]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
0
6
68
1601
lansoprazole; oral
A02BC03 [21600098]
A02BC03 [21600098]
2.3e-01
—
-1.0e+50
—
-1.0e+50
—
—
cases:4.81%
controls:3.86%
—
—
cases:0.00%
controls:0.34%
—
—
cases:0.00%
controls:0.43%
—
—
—
—
10
80
198
1991
—
0
7
208
2064
—
0
9
88
2060
—
—
Precordial pain
R07.2 [45568108]
R07.2 [45568108]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
0
6
68
1601
finasteride; oral
D11AX10 [21602350]
D11AX10 [21602350]
-2.1e-01
—
-1.0e+50
—
-1.0e+50
—
—
cases:2.40%
controls:2.95%
—
—
cases:0.00%
controls:0.72%
—
—
cases:0.00%
controls:0.58%
—
—
—
—
5
61
203
2010
—
0
15
208
2056
—
0
12
88
2057
—
—
Gastro-oesophageal reflux disease without oesophagitis
K21.9 [45538509]
K21.9 [45538509]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.34%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
0
7
208
2064
—
—
—
—
0
10
68
1597
Alcoholic cirrhosis of liver
K70.3 [45596343]
K70.3 [45596343]
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
cases:7.21%
controls:0.00%
—
—
—
—
—
—
—
—
—
15
0
193
2071
—
—
—
Other and unspecified hydronephrosis
N13.3 [45553432]
N13.3 [45553432]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
0
5
68
1602
Spondylosis, unspecified
M47.9 [45557887]
M47.9 [45557887]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
0
5
68
1602
scopolamine
A04AD01 [21600499]
A04AD01 [21600499]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.25%
cases:0.00%
controls:0.56%
—
—
—
—
—
0
5
81
2022
0
9
68
1598
Burn/scald
S14 [2002000979]
S14 [2002000979]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
0
6
68
1601
metoprolol and felodipine
C07FB02 [21601742]
C07FB02 [21601742]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
cases:0.00%
controls:0.35%
cases:0.00%
controls:0.75%
—
0
8
208
2063
—
—
—
0
7
81
2020
0
12
68
1595
Other forms of angina pectoris
I20.8 [45543166]
I20.8 [45543166]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.50%
—
—
—
—
—
—
0
8
68
1599
Excessive ear wax
H81 [2002000536]
H81 [2002000536]
1.3e-01
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:2.40%
controls:2.12%
cases:0.00%
controls:0.77%
—
—
—
—
—
—
cases:0.00%
controls:0.89%
cases:0.00%
controls:2.86%
5
44
203
2027
0
16
208
2055
—
—
—
0
18
81
2009
0
46
68
1561
hydrocortisone aceponate
D07AC16 [21602135]
D07AC16 [21602135]
3.9e-01
7.8e-01
—
—
-1.0e+50
—
9.2e-01
cases:9.13%
controls:6.37%
cases:4.81%
controls:2.27%
—
—
—
—
cases:0.00%
controls:0.34%
—
—
cases:14.71%
controls:6.41%
19
132
189
1939
10
47
198
2024
—
—
0
7
88
2062
—
10
103
58
1504
tinzaparin; parenteral
B01AB10 [21600981]
B01AB10 [21600981]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.81%
—
—
—
—
—
—
0
13
68
1594
Cystoscopy
UKC02 [2001306005]
UKC02 [2001306005]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.49%
—
0
14
208
2057
—
—
—
—
0
40
68
1567
Release of median nerve
ACC51 [2001300642]
ACC51 [2001300642]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
0
6
208
2065
—
—
—
—
—
0
5
68
1602
capecitabine
L01BC06 [21601440]
L01BC06 [21601440]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
208
2064
—
—
—
—
—
—
Other otitis externa
H60.8 [45567109]
H60.8 [45567109]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
208
2066
—
—
—
—
—
—
Osmolality of Urine
2695-5 [3026782]
2695-5 [3026782]
5.5e-01
7.4e-01
—
—
—
—
—
cases:6.25%
controls:3.72%
cases:2.88%
controls:1.40%
—
—
—
—
—
—
—
—
—
—
13
77
195
1994
6
29
202
2042
—
—
—
—
—
Benign neoplasm: Ascending colon
D12.2 [45600580]
D12.2 [45600580]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.50%
—
—
—
—
—
—
0
8
68
1599
Polysomnography panel
90568-7 [1002224]
90568-7 [1002224]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.68%
cases:0.00%
controls:0.43%
—
—
—
—
—
—
cases:0.00%
controls:0.25%
cases:0.00%
controls:0.87%
0
14
208
2057
0
9
208
2062
—
—
—
0
5
81
2022
0
14
68
1593
itraconazole; oral, parenteral
J02AC02 [21603081]
J02AC02 [21603081]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:1.35%
cases:0.00%
controls:0.34%
—
—
—
—
—
—
cases:0.00%
controls:0.30%
cases:0.00%
controls:1.24%
0
28
208
2043
0
7
208
2064
—
—
—
0
6
81
2021
0
20
68
1587
Spirometry at the office
SPAT1059 [2001700160]
SPAT1059 [2001700160]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
0
7
68
1600
Other malignant neoplasm of kidney, except renal pelvis
C64.88 [2000501096]
C64.88 [2000501096]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.34%
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
0
7
208
2064
0
5
208
2066
—
—
—
—
0
5
68
1602
Other chronic renal failure
N18.8 [45534123]
N18.8 [45534123]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.39%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.25%
cases:0.00%
controls:0.56%
0
8
208
2063
—
—
—
—
0
5
81
2022
0
9
68
1598
Left sided colitis
K51.5 [45533604]
K51.5 [45533604]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
208
2061
—
—
—
—
—
—
Blepharitis
H01.0 [45533180]
H01.0 [45533180]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.34%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.50%
0
7
208
2064
—
—
—
—
—
0
8
68
1599
famotidine; oral, parenteral
A02BA03 [21600084]
A02BA03 [21600084]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
0
6
68
1601
Other ill-defined and unspecified causes of mortality
R99 [45606834]
R99 [45606834]
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
cases:9.62%
controls:0.00%
—
—
—
—
—
—
—
—
—
20
0
188
2071
—
—
—
Epstein Barr virus capsid IgM Ab [Units/volume] in Serum by Immunoassay
5159-9 [3007844]
5159-9 [3007844]
1.8e+00
—
—
—
—
—
-1.0e+50
cases:2.88%
controls:0.48%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
6
10
202
2061
—
—
—
—
—
0
6
68
1601
Calcium [Moles/volume] in Serum or Plasma
2000-8 [3015377]
2000-8 [3015377]
4.3e-01
6.2e-01
—
—
—
—
—
cases:7.69%
controls:5.17%
cases:3.37%
controls:1.83%
—
—
—
—
—
—
—
—
—
—
16
107
192
1964
7
38
201
2033
—
—
—
—
—
Infective dermatitis
L30.3 [45577034]
L30.3 [45577034]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
0
5
68
1602
pH of Specimen
17433-4 [3019225]
17433-4 [3019225]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.35%
cases:0.00%
controls:1.06%
—
—
—
—
—
0
7
81
2020
0
17
68
1590
Benign lipomatous neoplasm of skin and subcutaneous tissue of trunk
D17.1 [45566667]
D17.1 [45566667]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
208
2065
—
—
—
—
—
—
Gastrointestinal bacterial pathogens panel - Stool by NAA with probe detection
92695-6 [37019628]
92695-6 [37019628]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
0
6
68
1601
Plain photography of ocular fundus
CK2S4 [2001301455]
CK2S4 [2001301455]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.56%
—
—
—
—
—
—
0
9
68
1598
chlorhexidine
S02AA09 [21605155]
S02AA09 [21605155]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
—
0
12
81
2015
—
Reagin Ab [Titer] in Serum by VDRL
50690-7 [3029634]
50690-7 [3029634]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.39%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
0
8
208
2063
—
—
—
—
—
0
6
68
1601
hydroxychloroquine; oral
P01BA02 [21604889]
P01BA02 [21604889]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.68%
cases:0.00%
controls:0.53%
—
—
—
—
—
—
cases:0.00%
controls:0.49%
cases:0.00%
controls:0.81%
0
14
208
2057
0
11
208
2060
—
—
—
0
10
81
2017
0
13
68
1594
Leukocytes [#/volume] in Synovial fluid
26469-7 [3000475]
26469-7 [3000475]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.25%
—
—
—
—
—
—
—
0
5
81
2022
—
Pure hypercholesterolaemia
E78.0 [45542771]
E78.0 [45542771]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:3.73%
—
—
—
—
—
—
0
60
68
1547
Primary gonarthrosis, bilateral
M17.0 [45562648]
M17.0 [45562648]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
cases:0.00%
controls:1.43%
—
—
—
—
—
0
9
81
2018
0
23
68
1584
isradipine; oral, parenteral
C08CA03 [21601749]
C08CA03 [21601749]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
0
5
68
1602
Acute cystitis
N30.0 [45601724]
N30.0 [45601724]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.81%
—
—
—
—
—
—
0
13
68
1594
Parkinson disease
G20 [45538098]
G20 [45538098]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.54%
cases:0.00%
controls:1.56%
—
—
—
—
—
0
11
81
2016
0
25
68
1582
scopolamine; oral, parenteral
N05CM05 [21604666]
N05CM05 [21604666]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.25%
cases:0.00%
controls:0.56%
—
—
—
—
—
0
5
81
2022
0
9
68
1598
Human coronavirus RNA [Presence] in Specimen by NAA with probe detection
41001-9 [3042596]
41001-9 [3042596]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
208
2065
—
—
—
—
—
—
verapamil; oral, parenteral
C08DA01 [21601767]
C08DA01 [21601767]
1.5e+00
—
—
—
—
—
—
cases:2.88%
controls:0.63%
—
—
—
—
—
—
—
—
—
—
—
—
6
13
202
2058
—
—
—
—
—
—
Striking against or struck by other object(s)
W22 [45756260]
W22 [45756260]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.75%
—
—
—
—
—
—
0
12
68
1595
bromhexine; oral, parenteral
R05CB02 [21603381]
R05CB02 [21603381]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
0
5
68
1602
Spirometry for bronchospasm with prolonged evaluation after bronchodilator
113016006 [4010399]
113016006 [4010399]
9.4e-01
—
—
—
—
-1.0e+50
—
cases:3.85%
controls:1.55%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
8
32
200
2039
—
—
—
—
0
7
81
2020
—
Preparing and fitting the occlusal splint in the mouth
SHB00 [2001310410]
SHB00 [2001310410]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.39%
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
0
8
208
2063
0
5
208
2066
—
—
—
—
—
Teaching of medicine inhalation technique
SPAT1257 [2001700358]
SPAT1257 [2001700358]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
0
5
68
1602
fluticasone; nasal
R01AD08 [21605050]
R01AD08 [21605050]
-3.3e-01
—
—
—
-1.0e+50
-1.0e+50
—
cases:3.85%
controls:5.26%
—
—
—
—
—
—
cases:0.00%
controls:0.39%
cases:0.00%
controls:2.57%
—
—
8
109
200
1962
—
—
—
0
8
88
2061
0
52
81
1975
—
X-ray examination of the lungs in one projection
GD1PA [2001303645]
GD1PA [2001303645]
1.2e+00
—
—
—
—
—
—
cases:2.88%
controls:0.87%
—
—
—
—
—
—
—
—
—
—
—
—
6
18
202
2053
—
—
—
—
—
—
Sinus symptom/complaint
R09 [2002000890]
R09 [2002000890]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
0
11
68
1596
hydrocortisone
C05AA01 [21601608]
C05AA01 [21601608]
3.7e-01
7.3e-01
—
—
-1.0e+50
—
9.2e-01
cases:9.13%
controls:6.47%
cases:4.81%
controls:2.37%
—
—
—
—
cases:0.00%
controls:0.34%
—
—
cases:14.71%
controls:6.41%
19
134
189
1937
10
49
198
2022
—
—
0
7
88
2062
—
10
103
58
1504
Obstetrics / Gynecology
16 [38004461]
16 [38004461]
1.6e-02
—
—
—
—
—
—
cases:2.40%
controls:2.37%
—
—
—
—
—
—
—
—
—
—
—
—
5
49
203
2022
—
—
—
—
—
—
Methemoglobin/Hemoglobin.total in Venous blood
2617-9 [3024889]
2617-9 [3024889]
1.8e+00
—
—
—
—
-1.0e+50
—
cases:2.88%
controls:0.48%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
6
10
202
2061
—
—
—
—
0
10
81
2017
—
tioconazole
D01AC07 [21601926]
D01AC07 [21601926]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
208
2065
—
—
—
—
—
—
Bicarbonate [Moles/volume] in Arterial blood
1960-4 [3008152]
1960-4 [3008152]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.18%
—
—
—
—
—
—
0
19
68
1588
Guidance related to psychoactive substances / risk behaviour
SPAT1309 [2001700410]
SPAT1309 [2001700410]
2.3e+00
—
—
—
—
—
—
cases:2.40%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
—
5
5
203
2066
—
—
—
—
—
—
Metatarsalgia
M77.4 [45601544]
M77.4 [45601544]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
0
5
68
1602
Internal derangement of knee, unspecified
M23.9 [45567507]
M23.9 [45567507]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.25%
cases:0.00%
controls:0.81%
—
—
—
—
—
0
5
81
2022
0
13
68
1594
Acute bronchitis
J20 [45581849]
J20 [45581849]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.56%
—
—
—
—
—
—
0
9
68
1598
Retinal breaks without detachment
H33.3 [45596066]
H33.3 [45596066]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.50%
—
—
—
—
—
—
0
8
68
1599
Mucopurulent conjunctivitis
H10.0 [45596007]
H10.0 [45596007]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.25%
cases:0.00%
controls:0.31%
0
6
208
2065
—
—
—
—
0
5
81
2022
0
5
68
1602
Thyroid insufficiency
104 [2001600104]
104 [2001600104]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
208
2066
—
—
—
—
—
—
Attention to surgical dressings and sutures
Z48.0 [45609943]
Z48.0 [45609943]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
0
11
68
1596
clobetasol
D07AD01 [21602141]
D07AD01 [21602141]
3.3e-01
—
—
—
—
—
—
cases:2.40%
controls:1.74%
—
—
—
—
—
—
—
—
—
—
—
—
5
36
203
2035
—
—
—
—
—
—
Other hammer toe(s) (acquired)
M20.4 [45562664]
M20.4 [45562664]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
208
2066
—
—
—
—
—
—
Differential panel, method unspecified - Blood
69738-3 [42870588]
69738-3 [42870588]
6.9e-01
8.8e-01
1.5e+00
—
—
—
—
cases:11.54%
controls:6.13%
cases:6.73%
controls:2.90%
cases:2.40%
controls:0.53%
—
—
—
—
—
—
—
—
24
127
184
1944
14
60
194
2011
5
11
203
2060
—
—
—
—
Gliadin peptide IgA Ab [Units/volume] in Serum by Immunoassay
63453-5 [40766183]
63453-5 [40766183]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
208
2065
—
—
—
—
—
—
Other shoulder lesions
M75.8 [45572543]
M75.8 [45572543]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
208
2065
—
—
—
—
—
—
chloramphenicol
S02AA01 [21605147]
S02AA01 [21605147]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
cases:0.00%
controls:0.93%
—
—
—
—
—
0
9
81
2018
0
15
68
1592
brompheniramine, combinations
R06AB51 [21603466]
R06AB51 [21603466]
1.3e-01
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:2.40%
controls:2.12%
cases:0.00%
controls:0.82%
—
—
—
—
—
—
cases:0.00%
controls:0.89%
cases:0.00%
controls:2.43%
5
44
203
2027
0
17
208
2054
—
—
—
0
18
81
2009
0
39
68
1568
EKG study
11524-6 [3013512]
11524-6 [3013512]
-2.8e-01
3.2e-01
—
—
-1.0e+50
—
—
cases:4.81%
controls:6.28%
cases:3.37%
controls:2.46%
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
10
130
198
1941
7
51
201
2020
—
—
0
8
88
2061
—
—
Other dental caries
K02.8 [45586690]
K02.8 [45586690]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
0
5
68
1602
mirabegron; oral
G04BD12 [43534790]
G04BD12 [43534790]
—
—
—
—
-1.0e+50
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
cases:0.00%
controls:1.12%
—
—
—
—
0
9
88
2060
—
0
18
68
1589
Acute subendocardial infarction unspecified coronary artery status
I21.49 [2000502437]
I21.49 [2000502437]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
0
6
68
1601
Otolaryngology
4 [38004449]
4 [38004449]
-4.5e-02
1.4e-01
—
—
-1.0e+50
—
—
cases:7.69%
controls:8.02%
cases:3.37%
controls:2.95%
—
—
—
—
cases:0.00%
controls:0.63%
—
—
—
—
16
166
192
1905
7
61
201
2010
—
—
0
13
88
2056
—
—
Free T4 and TSH panel - Serum or Plasma
24348-5 [3001019]
24348-5 [3001019]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
0
6
208
2065
—
—
—
—
0
7
68
1600
empagliflozin; oral
A10BK03 [1123740]
A10BK03 [1123740]
—
2.5e-01
—
—
—
—
—
—
—
cases:2.40%
controls:1.88%
—
—
—
—
—
—
—
—
—
—
—
5
39
203
2032
—
—
—
—
—
budesonide; nasal
R01AD05 [21605047]
R01AD05 [21605047]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
0
5
68
1602
hydrocortisone; local oral
A01AC03 [21600036]
A01AC03 [21600036]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
0
10
81
2017
—
naproxen; oral, rectal
M01AE02 [21603968]
M01AE02 [21603968]
-9.0e-01
—
—
—
-1.0e+50
-1.0e+50
4.1e-01
cases:3.37%
controls:7.92%
—
—
—
—
—
—
cases:0.00%
controls:0.34%
cases:0.00%
controls:2.27%
cases:10.29%
controls:7.09%
7
164
201
1907
—
—
—
0
7
88
2062
0
46
81
1981
7
114
61
1493
Cholesterol in HDL/Cholesterol.total [Molar ratio] in Serum or Plasma
70200-1 [42868674]
70200-1 [42868674]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:1.26%
—
—
—
—
—
—
cases:0.00%
controls:1.18%
cases:0.00%
controls:2.24%
—
0
26
208
2045
—
—
—
0
24
81
2003
0
36
68
1571
SARS-CoV-2 (COVID-19) Ag [Presence] in Upper respiratory specimen by Immunoassay
96119-3 [36032419]
96119-3 [36032419]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.48%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
0
10
208
2061
—
—
—
—
—
0
6
68
1601
Other specified bacterial intestinal infections
A04.8 [45561679]
A04.8 [45561679]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
208
2066
—
—
—
—
—
—
metformin and sitagliptin
A10BD07 [21600772]
A10BD07 [21600772]
-1.0e+50
-1.0e+50
-1.0e+50
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:1.01%
cases:0.00%
controls:0.77%
cases:0.00%
controls:0.29%
—
—
—
—
cases:0.00%
controls:0.79%
cases:0.00%
controls:1.18%
0
21
208
2050
0
16
208
2055
0
6
208
2065
—
—
0
16
81
2011
0
19
68
1588
LabWAS
↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
125
1765
0.27
17.81
50.6
26.3
4.30
4.56
e12/l
5.43
120
1728
125
1765
0.27
17.81
50.9
26.4
217.28
233.38
e9/l
1.61
120
1733
111
1659
0.29
16.78
5.6
6.2
2.45
2.61
mmol/l
1.08
100
1545
106
1621
0.30
16.63
4.9
5.4
1.27
1.33
mmol/l
0.77
95
1504
107
1623
0.30
16.23
5.0
5.5
4.33
4.42
mmol/l
0.36
96
1515
63
218
3.71
15.56
3.7
2.2
2.17
1.67
%
1.50
55
187
124
1726
0.31
14.88
19.9
12.8
36.62
28.91
u/l
2.84
119
1683
67
1231
0.33
12.83
4.0
5.2
2.19
2.55
ug/l
0.34
58
1121
111
1602
0.35
12.74
5.4
5.4
6.44
6.15
mmol/l
0.88
97
1482
108
1576
0.35
12.57
4.5
4.6
1.62
1.35
mmol/l
2.41
95
1453
112
1587
0.37
11.38
38.5
17.2
83.52
79.04
ml/min/173m2
1.12
106
1479
112
1582
0.37
11.09
6.5
7.0
41.05
40.37
mmol/mol
0.23
98
1500
36
113
3.64
10.01
5.5
3.5
24.11
23.97
mmol/l
0.09
36
113
120
1624
0.39
9.95
39.4
17.9
31.73
27.98
mg/l
0.67
113
1371
50
992
0.35
9.94
3.8
4.4
18.89
21.45
%
0.91
23
481
49
202
2.86
8.64
5.3
3.9
2.53
1.62
mmol/l
0.78
44
171
50
209
2.83
8.59
5.3
4.0
5.82
5.73
kpa
0.22
50
203
39
144
3.10
8.33
3.2
2.9
27.15
36.11
u/l
0.85
34
123
42
165
2.93
8.05
2.4
2.6
0.21
0.21
g/l
0.03
37
151
108
1460
0.46
6.95
4.6
4.3
1.91
2.01
mu/l
0.46
97
1315
39
176
2.49
5.63
5.1
3.1
4.46
4.49
kpa
0.03
39
169
54
890
0.47
5.41
3.4
2.6
—
—
—
0
0
78
1135
0.50
5.41
3.8
3.4
15.32
14.80
pmol/l
0.89
71
1019
41
728
0.46
4.90
2.3
3.3
0.61
0.79
ug/l
0.92
33
474
39
702
0.45
4.82
5.6
3.8
0.00
0.03
estimate
0.78
12
168
38
676
0.46
4.46
1.7
2.1
1.88
1.41
mmol/l
1.34
32
563
39
196
2.22
4.39
3.0
4.0
17.91
10.27
umol/l
0.58
33
177
93
1230
0.56
4.07
3.6
4.2
16.91
12.17
mm/h
1.61
86
1145
27
505
0.47
3.48
5.0
3.4
0.00
0.01
estimate
0.50
12
155
63
900
0.57
3.39
4.3
3.9
0.00
0.00
estimate
-0.00
11
174
12
34
3.68
3.25
1.4
1.5
—
—
—
0
0
12
34
3.68
3.25
1.4
1.5
—
—
—
0
0
6
194
0.29
3.14
3.0
4.3
2.83
74.01
ug/l
—
6
169
62
876
0.58
3.11
3.8
3.9
0.00
0.00
estimate
-0.00
12
192
63
885
0.59
3.08
4.3
3.9
0.00
8.33
estimate
0.50
12
195
42
247
1.88
3.06
24.5
9.0
1.29
0.72
mmol/l
0.22
37
204
12
275
0.40
2.54
3.3
2.4
10.93
13.91
nmol/l
0.48
12
250
22
110
2.12
2.52
1.6
1.5
—
—
—
0
0
31
505
0.55
2.51
5.7
3.8
0.00
0.01
estimate
0.50
12
168
6
13
4.72
2.29
1.0
2.2
95.17
91.92
%
—
6
13
78
584
1.54
2.26
3.7
3.8
51.85
35.97
u/l
1.75
73
555
38
248
1.65
1.94
2.3
2.0
—
—
—
0
0
20
108
1.94
1.89
1.7
1.7
—
—
—
0
0
8
29
2.83
1.81
5.6
3.6
—
—
—
0
0
8
177
0.43
1.80
3.8
2.9
0.29
0.19
e6/l
—
8
171
5
13
3.91
1.72
2.2
1.7
—
—
—
0
0
9
189
0.45
1.72
2.3
1.4
—
—
—
0
0
38
256
1.59
1.72
2.2
1.9
—
—
—
0
0
10
202
0.47
1.56
29.8
8.7
—
—
—
0
0
115
1309
0.73
1.43
13.4
9.0
89.27
80.99
u/l
1.05
110
1246
61
767
0.71
1.43
7.5
4.0
31.09
45.46
ng/l
1.12
50
594
0
40
0.00
1.34
0.0
1.3
—
—
—
0
0
8
34
2.41
1.30
1.0
1.2
—
—
—
0
0
57
447
1.38
1.21
3.1
2.0
2.53
2.96
mg/l
0.87
52
394
5
20
2.54
1.16
1.2
1.3
187.20
312.00
u/l
—
5
20
53
661
0.73
1.13
3.7
4.1
19.24
10.13
mg/mmol
0.46
41
438
55
682
0.74
1.13
2.0
2.4
64.61
73.32
nmol/l
1.01
50
605
26
366
0.67
1.11
2.3
1.8
448.56
37864509.22
pmol/l
0.50
18
309
28
388
0.68
1.10
5.9
4.2
1.02
1.02
kg/l
0.10
22
261
10
52
1.97
1.08
1.5
1.3
—
—
—
0
0
7
34
2.09
1.04
1.0
1.2
348.86
274.75
u/ml
—
7
16
43
331
1.38
1.02
2.4
2.0
—
—
—
0
0
10
54
1.89
0.98
1.2
1.4
—
—
—
0
0
0
30
0.00
0.98
0.0
4.1
—
1147.83
—
0
6
25
176
1.48
0.96
4.6
2.7
7.97
8.41
ug/l
0.04
25
159
42
328
1.35
0.92
3.1
3.0
1.87
1.02
e6/l
0.35
28
192
63
532
1.26
0.79
3.3
3.2
1.33
0.45
e6/l
0.84
51
397
7
38
1.87
0.74
2.0
1.3
—
—
—
0
0
7
38
1.87
0.74
2.0
1.3
—
—
—
0
0
5
92
0.53
0.68
3.2
1.8
198.60
213.84
pmol/l
—
5
82
5
94
0.52
0.68
1.8
2.1
—
—
—
0
0
46
381
1.27
0.67
9.2
1.7
1.51
1.63
mg/l
0.14
36
309
11
70
1.60
0.66
1.0
3.2
1.42
2.80
ratio
—
5
37
38
308
1.29
0.66
3.2
3.2
1.40
0.60
e6/l
0.35
24
173
68
774
0.82
0.65
3.7
3.0
—
—
estimate
—
0
0
6
103
0.57
0.64
1.8
2.3
—
17.22
—
0
10
18
131
1.41
0.61
2.1
1.6
—
—
—
0
0
88
973
0.83
0.61
7.3
10.2
4.73
4.31
e9/l
0.86
76
845
102
928
1.19
0.60
12.2
7.6
15.34
12.70
umol/l
1.44
97
892
7
114
0.60
0.60
3.0
1.8
37.14
41.79
nmol/l
—
7
108
8
55
1.47
0.56
2.0
1.3
—
—
—
0
0
10
147
0.66
0.56
6.1
2.9
5.17
5.07
kpa
—
10
142
11
74
1.51
0.54
1.9
3.4
—
—
—
0
0
11
75
1.49
0.52
1.4
2.3
49.00
44.95
u/l
—
6
69
20
255
0.76
0.50
1.2
1.3
27.84
31.88
iu/ml
—
7
74
10
68
1.49
0.48
1.3
2.9
11.72
11.46
g/l
—
10
60
49
557
0.84
0.45
2.6
3.3
2.34
2.33
mmol/l
0.18
42
499
5
32
1.58
0.42
1.2
1.1
—
—
—
0
0
0
15
0.00
0.41
0.0
9.1
—
120.50
—
0
6
0
16
0.00
0.41
0.0
1.1
—
—
—
0
0
0
16
0.00
0.41
0.0
1.7
—
3.00
—
0
9
70
767
0.87
0.40
2.1
2.1
81.72
93.78
pmol/l
1.56
45
425
13
170
0.75
0.40
2.0
2.1
430.69
375.14
nmol/l
0.88
13
156
13
98
1.35
0.38
1.9
2.0
5.48
2.15
ug/l
0.42
13
90
12
92
1.32
0.32
1.5
1.5
1.35
1.45
g/l
0.22
12
86
90
844
1.12
0.30
16.3
8.2
1.16
1.20
mmol/l
3.42
78
732
28
242
1.18
0.30
16.5
4.7
235.00
234.39
u/l
0.01
28
230
23
195
1.20
0.30
5.3
3.5
—
—
—
0
0
19
222
0.84
0.25
1.1
1.3
14.18
7.37
u/ml
—
6
82
10
78
1.30
0.24
1.3
2.7
3.00
3.01
g/l
—
10
70
16
134
1.21
0.23
14.0
7.8
24.93
24.50
mmol/l
0.12
16
128
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
1.5
—
—
—
0
0
0
10
0.00
0.21
0.0
2.5
—
13.40
—
0
10
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
2.1
—
—
—
0
0
0
12
0.00
0.21
0.0
1.0
—
34.88
—
0
6
0
12
0.00
0.21
0.0
1.0
—
—
—
0
0
0
12
0.00
0.21
0.0
1.0
—
516.00
—
0
7
0
12
0.00
0.21
0.0
1.0
—
—
—
0
0
5
43
1.17
0.21
1.2
1.4
—
—
—
0
0
0
13
0.00
0.21
0.0
1.1
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
6
48
1.26
0.20
1.2
1.4
—
—
—
0
0
0
14
0.00
0.20
0.0
1.4
—
—
—
0
0
0
14
0.00
0.20
0.0
1.1
—
—
—
0
0
6
51
1.18
0.19
1.3
1.2
—
—
—
0
0
6
52
1.16
0.19
1.3
1.5
—
—
—
0
0
7
61
1.15
0.17
1.3
1.5
—
—
—
0
0
31
339
0.90
0.17
2.7
3.0
2.50
2.44
mmol/l
1.59
26
299
10
82
1.23
0.17
1.3
2.7
3.85
3.64
g/l
—
10
74
10
82
1.23
0.17
1.3
2.7
4.38
4.26
g/l
—
10
74
10
82
1.23
0.17
1.3
2.7
6.89
7.34
g/l
—
10
74
5
68
0.73
0.17
5.8
4.2
4.74
4.61
pmol/l
—
5
62
33
309
1.08
0.11
2.1
1.7
1286.58
1209.04
nmol/l
0.13
27
240
48
503
0.94
0.10
1.9
1.8
17.68
19.65
nmol/l
0.52
43
421
42
401
1.06
0.09
4.0
2.6
—
—
—
0
0
59
570
1.05
0.08
5.0
3.0
57.13
64.30
u/l
0.33
54
539
15
144
1.04
0.00
1.6
1.4
—
—
—
0
0
13
134
0.97
0.00
2.8
4.1
1.18
1.22
mmol/l
1.40
13
116
0
9
0.00
0.00
0.0
4.9
—
90.33
—
0
9
0
9
0.00
0.00
0.0
1.2
—
53.92
—
0
9
0
9
0.00
0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
8.25
—
0
5
0
6
0.00
-0.00
0.0
7.0
—
169.28
—
0
6
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.8
—
95.34
—
0
8
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
-0.00
0.0
2.4
—
—
—
0
0
0
7
0.00
-0.00
0.0
2.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.8
—
1.56
—
0
5
5
49
1.02
-0.00
1.4
1.4
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
2.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
1.17
—
0
5
6
68
0.88
-0.00
1.7
1.6
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.7
—
12.67
—
0
6
0
8
0.00
-0.00
0.0
1.0
—
1481.13
—
0
8
0
7
0.00
-0.00
0.0
2.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
4.2
—
65.10
—
0
5
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
7.4
—
10.18
—
0
5
0
8
0.00
-0.00
0.0
2.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
7.24
—
0
5
0
7
0.00
-0.00
0.0
2.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
100.00
—
0
6
0
8
0.00
-0.00
0.0
1.0
—
41.69
—
0
8
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.1
—
33.09
—
0
8
0
5
0.00
-0.00
0.0
1.4
—
1.11
—
0
5
0
5
0.00
-0.00
0.0
3.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
7.4
—
4.66
—
0
5
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
6
64
0.94
-0.00
1.7
1.5
—
—
—
0
0
5
50
1.00
-0.00
1.4
1.3
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.1
—
116.14
—
0
8
0
7
0.00
-0.00
0.0
2.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint I9_CARDMYOALC and mortality.
Females
No dataMales
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| I9_CARDMYOALC | 8.396 [6.95, 10.14] | < 0.001 |
| Birth year | 0.986 [0.98, 1.0] | 0.003 |
During the follow-up period (1.1.1998 — 31.12.2019), 408 out of 630 males with I9_CARDMYOALC died.
Mortality risk
Mortality risk for people of age
years, who have I9_CARDMYOALC.| N-year risk | Females | Males |
|---|---|---|
| 1 | No data | 1.353% |
| 5 | No data | 8.938% |
| 10 | No data | 20.736% |
| 15 | No data | 36.196% |
| 20 | No data | 53.948% |
Relationships between endpoints
↥Index endpoint: I9_CARDMYOALC – Alcoholic cardiomyopathy
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data